

HHS Public Access

Author manuscript *Fertil Steril*. Author manuscript; available in PMC 2021 November 09.

Published in final edited form as: *Fertil Steril.* 2020 October ; 114(4): 690–714. doi:10.1016/j.fertnstert.2020.08.1423.

Current evidence supporting a goal of singletons: a review of maternal and perinatal outcomes associated with twin versus singleton pregnancies after in vitro fertilization and intracytoplasmic sperm injection

Abey Eapen, Ph.D.^a, Ginny L. Ryan, M.D.^a, Patrick Ten Eyck, Ph.D.^b, Bradley J. Van Voorhis, M.D.^a

^aDepartment of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa

^bInstitute for Clinical and Translational Science, University of Iowa, Iowa City, Iowa

Abstract

With increasing use of in vitro fertilization and intracytoplasmic sperm injection (IVF-ICSI) almost 2% of all babies born in the United States each year are now conceived with these technologies, making outcomes of IVF-ICSI extremely important not only to patients and families but to public health. Twin pregnancy rates after IVF-ICSI in the United States have declined since their peak in 2013 but remain at approximately 1 in 10 to 1 in 20 pregnancies. A review of the current international literature on twin versus singleton pregnancy outcomes after IVF-ICSI treatment confirms statistically significantly higher risks to maternal and perinatal health and statistically significantly higher twin pregnancy rates to an absolute minimum to maximize the safety of these medical treatments.

Keywords

Health care costs; infertility; in vitro fertilization; maternal outcomes; multiple gestation pregnancy; perinatal outcomes; twins

In spontaneously conceived pregnancies, monozygous twining happens about 0.4% of the time and dizygous twinning 1.2% of the time (1). The former rate is relatively stable across populations while the latter rate varies by maternal age and parity, race, sex of the embryos, and season. In addition, and most remarkably, the rate of dizygous twin pregnancies can be increased iatrogenically when ovarian hyperstimulation or multiple embryo transfer after in vitro fertilization (IVF) is used to increase the efficiency of fertility treatment (2). Such treatments also increase the rates of triplet and higher order multiple gestation pregnancies.

Reprint requests: Abey Eapen, Ph.D., Reproductive Endocrinology and Infertility Division, Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, abey-eapen@uiowa.edu.

A.E. has nothing to disclose. G.L.R. has nothing to disclose. P.T. has nothing to disclose. B.J.V. has nothing to disclose.

Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility-and-sterility/posts/30602

For the first two decades after such fertility treatments were introduced in the United States in the early 1980s, the rate of twin pregnancies nearly doubled, and the rate of triplet and higher order multiple gestation pregnancies quadrupled in the United States. Triplet and higher order multiple gestation birth rates began to fall in 1998, but twin rates continued to climb during the new millennium (3). Although a trend in increasing maternal age was responsible for a small part of these increases, practices in fertility treatment and the increasing rate of use of these treatments were the biggest factors responsible (4). Indeed, fertility treatment was the reason for one-third of all twin pregnancies and three quarters of all triplet and higher order multiple gestation pregnancies in the United States by 2013, when the percentage of twin live births from IVF ranged from 8.2% for women older than 42 years to 28.3% for women younger than 35 years (5, 6).

Thanks to an increasing awareness of the risks of multiple gestation pregnancies and efforts from leadership in the field of infertility care to encourage practice changes, twin rates have begun to decline slowly but steadily since that time. Preliminary 2018 data (pregnancy rates per procedure performed) from the Society for Assisted Reproductive Technology (SART) show a range of twin live-birth rates from 5.1% for women older than 42 years to 10.4% for women younger than 35 years (7). While laudable, the goal of our fertility treatments is to return our patients to normal health and well-being with one healthy baby per pregnancy. With that goal in mind, it is valuable to review the full scope of available international data on the risks of twin, triplet, and higher order multiple pregnancies for women, their pregnancies, their offspring, and their families, and to consider the increased costs to families and health care system.

MATERIALS AND METHODS

Literature search

We performed a review to identify studies of maternal and fetal outcomes for twin and multiple pregnancies compared with singleton pregnancies. The electronic databases OVID Medline and OVID EMBASE were searched for primary articles published from inception until February 2020. We performed a search using the MeSH terms "assisted reproductive techniques" AND "multiple pregnancy." We subsequently supplemented the search with text words to include different outcomes associated with maternal morbidity and mortality; fetal morbidity and mortality; and social and societal outcomes. The different maternal and fetal outcomes covered within the scope of this review are listed in the data extraction section. The search strategy (search terms and corresponding MeSH terms) is detailed in Supplemental Tables 1 and 2 (available online). The reference lists of all eligible studies were hand-searched to identify any additional studies.

Study selection

An overview of study inclusion is detailed in Figure 1. We included studies that met the following criteria: all studies where women achieved a pregnancy after assisted reproductive technology (ART) treatment; the pregnancy resulted in twins, triplets, or a higher order pregnancy; the outcome variable specifically related to maternal or fetal aspects (morbidity or mortality); and the respective studies (registry and cohort studies) had categorical

data that distinguished singleton pregnancy outcomes from twin pregnancy outcomes (for comparison) because the health outcomes of twins and not triplets or higher order multiple pregnancies are the focus of this review.

Any study that reported data from ART treatments other than IVF and intracytoplasmic sperm injection (ICSI) was excluded. Studies reporting outcomes or comparisons exclusive to naturally conceived singleton pregnancy or multiple order pregnancy were excluded. Letters, case reports, case series, expert reviews, and data that were presented as an abstract or oral presentation were also excluded from analysis. After removing the duplicates, two reviewers (A.E. and G.R.) independently screened the search results and assessed the eligibility of studies for inclusion by scanning the titles and abstracts. Any disagreements were resolved by a third reviewer (B.J.V.) during the team meeting every 2 weeks. No institutional board review approval was needed for this study because no patient-identifiable data was used for the review.

Data extraction

The following data were extracted for the included studies: first author, year, study design, patient demographics, and maternal and fetal outcomes. Categorical data were collected for both maternal and fetal outcomes. The data extraction was checked by a second reviewer. The studies that assessed maternal outcomes are presented in Table 1. The maternal outcomes we assessed included maternal hospitalization, cesarean delivery, gestational diabetes mellitus (GDM), antepartum hemorrhage, including placental abruption and placenta previa, pregnancy-induced hypertension, postpartum hemorrhage, preterm labor, and preeclampsia.

The studies that assessed fetal outcomes are presented in Table 1. The fetal outcomes assessed included congenital anomalies, preterm birth rate (<37 weeks of gestation), early preterm birth rate (<32 weeks of gestation), very preterm birth rate (<28 weeks of gestation), low birth weight (<2,500 grams), neonatal intensive care unit (NICU)/special care baby unit (SCBU) admission rate, mean gestational age in weeks, mean birth weight in grams, perinatal mortality rate, and stillbirth rate. All data are expressed in percentages except mean gestational age (in weeks) and mean birth weight (in grams). Other social and societal outcomes included (for which a direct comparison was not possible) are presented in Table 2: hospital admission charges (maternal and neonatal or combined costs) and maternal stress and depression.

Statistical analysis

For each maternal and fetal outcome, data was extracted as a 2×2 table in an Excel file. For analytic purposes, we categorized outcome data (where available) separately based on different treatment interventions (e.g., autologous oocytes, donor oocytes, and frozen embryo transfer). The study statistician (P.T.) performed meta-analysis as appropriate for the relevant data.

Meta-analyses for comparisons of means and proportions were performed using the R functions *metacont* and *metabin*, respectively, from the meta package (https://cran.r-project.org/web/packages/meta/index.html). Mean differences or odds ratios (OR) and their

95% confidence intervals (CI) were calculated for each study within a set and used the random effects weights for calculating the aggregate statistics. This information is expressed numerically and visually using forest plots constructed with the *forest* function in R. Statistics for the heterogeneity of each set of studies are included in each plot. Statistical heterogeneity and impact of heterogeneity on meta-analysis were performed. We used I² statistics to assess the impact of heterogeneity on the meta-analysis.

RESULTS

A total of 60 studies were included in the review. The initial search of the Medline and EMBASE databases identified 432 potentially relevant articles. After screening the titles and abstracts, 86 full texts were obtained for detailed review. A total of 26 full articles were excluded where studies did not have any primary data on singleton pregnancy outcomes (for comparison). An additional 22 studies were identified through examination of reference list of full articles. The identification of study selection is shown in Figure 1.

We divided the selected manuscripts to studies with maternal and fetal outcomes (Table 1) for the meta-analysis; and studies with societal outcomes (financial aspects, maternal stress and depression, fetal and child development) for a narrative review (Table 2). The 60 studies that met the inclusion criteria were all published in English up to February 2020. Even though there were no language restrictions applied in the study identification phase, only articles with a full English translation were included in the final analysis. Out of the studies identified, 17 were from North America, four from South America, 28 from Europe, six from Asia, and five from Australia.

Maternal outcomes

Maternal outcomes were assessed based on the proportion of occurrence per pregnancy episode. See Table 3 for a summary of effect sizes and heterogeneity for each maternal outcome.

Antenatal hospitalization.—Six studies reported outcomes of antenatal hospitalization: one registry-based study (FIVNAT register) along with five cohort studies (Fig. 2). The outcomes data for Gerris et al. (41) were for singleton and twin pregnancies resulting from a double-embryo transfer. Indications for hospitalization in these studies included secondary ovarian hyperstimulation syndrome, heterotopic pregnancies, hyperemesis gravidarum, antepartum hemorrhage, and cholestasis of pregnancy. Goldfarb et al. (35) included multiple episodes of hospital admissions in some women due to threatened preterm labor. The OR of antenatal hospitalization was 2.6 (95% CI) 1.9–3.5) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was a moderate level of heterogeneity $(I^2 = 52\%, P=.05)$ within the studies included.

Cesarean delivery.—Sixteen studies reported the outcome of cesarean delivery: one registry study (FIVNAT, 1996) and 15 cohort studies (Fig. 3). We combined data for elective and emergency cesarean delivery together for this analysis. Only primary cesarean delivery rates were analyzed. Ombelet et al. (45) reported data for IVF treatment cycles and ICSI treatment cycles separately. Stoop et al. (43) and Van Dorp et al. (47) reported

data separately for autologous cycles and oocyte donor cycles. Luke et al. (38) mentioned separate data sets for fresh and frozen autologous cycles and fresh and frozen oocyte donor treatment cycles. Pereira et al. (57) reported data for natural cycle frozen embryo transfers separately from frozen embryo transfers after hormone treatment. The OR of cesarean delivery was 3.7 (95% CI, 3.3–4.1) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was a statistically significant heterogeneity ($I^2 = 93\%$, P < .01) within the studies included.

Gestational diabetes mellitus.—Seven cohort studies reported outcomes of GDM, although the definition and diagnostic criteria for GDM were unclear from the studies (Fig. 4). Data for pregestational diabetes were excluded. The OR of GDM was 1.2 (95% CI, 1.1–1.3) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestation. There was a moderate heterogeneity ($I^2 = 58\%$, *P*<.01) in the included studies.

Antepartum hemorrhage: placental abruption.—Four cohort studies reported the outcome of placental abruption (Fig. 5). We excluded studies that reported combined data on multiple reasons for antepartum hemorrhage (e.g., all cases of placental abruption, placenta previa, and other causes of hemorrhage reported together). The OR of placental abruption was 1.3 (95% CI, 1.2–1.5) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was a minimal heterogeneity ($I^2 = 0\%$, *P*=.82) in the included studies.

Antepartum hemorrhage: placenta previa.—Four cohort studies reported the outcome of placenta previa (Fig. 6). We excluded studies that reported combined data on multiple reasons for antepartum hemorrhage (e.g., all cases of placental abruption, placenta previa, and other causes of hemorrhage reported together). The grade of severity of placenta previa was unclear from the studies. The OR of placental abruption was 0.8 (95% CI, 0.7–0.9) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was a moderate heterogeneity ($I^2 = 66\%$, *P*=.01) in the included studies.

Pregnancy-induced hypertension.—Seven cohort studies reported the outcome of pregnancy-induced hypertension (Fig. 7). Stoop et al. (43) defined pregnancy-induced hypertension as blood pressure levels >140/90 mm Hg on two or more occasions at least 6 hours apart, without proteinuria, after 20 weeks. Data for pregestational hypertension was excluded. The odds ratio of having pregnancy-induced hypertension was 2.0 (95% CI, 1.9–2.3) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestation. There was a moderate heterogeneity ($I^2 = 78\%$, *P*<.01) in the included studies.

Postpartum hemorrhage.—Five studies reported the outcome of postpartum hemorrhage: one registry study (FIVNAT) and four cohort studies (Fig. 8). The odds ratio of having postpartum hemorrhage was 2.2 (95% CI, 1.2–4.1) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was a statistically significant heterogeneity ($I^2 = 91\%$, *P*<.01) in the included studies.

Preterm labor.—Five cohort studies reported the outcome of preterm labor (Fig. 9). The diagnostic criteria for preterm labor were not mentioned in any of the studies. Goldfarb et

al. (35) reported multiple episodes of hospital admission for some patients with preterm labor. The odds ratio of having preterm labor was 6.3 (95% CI, 3.6–11.0) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was statistically significant heterogeneity ($I^2 = 91\%$, *P*<.01) in the included studies.

Preeclampsia.—Five cohort studies reported the outcome of preeclampsia (Fig. 10). This was defined as repeated blood pressure levels over 140/90 mm Hg with proteinuria more than 0.3 g/day after 20 weeks of gestation. The odds ratio of having preeclampsia was 1.9 (95% CI, 1.4–2.6) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was statistically significant heterogeneity ($I^2 = 40\%$, *P*=.12) in the included studies.

Fetal outcomes

Fetal outcomes were assessed based on proportion of occurrence calculated per infant. See Table 4 for a summary of effect sizes and heterogeneity for each fetal and neonatal outcome.

Congenital anomalies.—A total of 19 studies reported outcomes of congenital anomalies: eight registry studies and 11 cohort studies (Fig. 11). The majority of the non-European studies classified congenital anomalies based on the *International Classification of Disease and Related Health Problems*, 10th edition (ICD-10) code each malformation. Congenital anomalies or malformation included a single disorder or multiple disorders, and we combined the available primary data for this analysis. Studies from Europe reported congenital anomalies according to the European Registration of Congenital Anomalies and Twins (EUROCAT) guidelines. The odds ratio of having a congenital anomaly was 1.1 (95% CI, 1.0–1.2) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was minimal heterogeneity ($I^2 = 0$; *P*=.84) within the studies included.

Preterm birth rate.—A total of 43 studies reported outcomes of preterm birth: 23 registry studies and 20 cohort studies (Fig. 12). Preterm birth was defined as delivery before 37 completed weeks of gestation. The odds ratio of preterm birth was 8.3 (95% CI, 7.8–8.9) in IVF-ICSI twin gestations when compared to singleton IVF-ICSI gestations. There was statistically significant heterogeneity ($I^2 = 97\%$, *P*<.01) within the studies included.

Early preterm birth rate.—A total of 14 studies reported outcomes for early preterm birth (EPTB), defined as birth before 32 completed weeks of gestation, which included 13 registry studies and one cohort studies (Fig. 13). Luke et al. (38) included separate data sets for fresh and frozen autologous cycles and fresh and frozen oocyte donor treatment cycles. The odds ratio of EPTB was 3.5 (95% CI, 3.1–3.9) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was statistically significant heterogeneity ($I^2 = 88\%$, *P*<.01) within the studies included.

Very preterm birth rate.—A total of 30 studies reported outcomes for very preterm birth rate (VPTBR), defined as birth before 28 completed weeks of gestation, which included 17 registry studies and 13 cohort studies (Fig. 14). The odds ratio of VPTBR was 5.5 (95% CI, 5.2–5.9) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI

gestations. There was statistically significant heterogeneity ($I^2 = 82\%$, *P*<.01) within the studies included.

Low birth weight.—A total of 29 studies reported outcomes for low birth weight (LBW), defined as birth weight <2,500 grams, which included 11 registry studies and 18 cohort studies (Fig. 15). The odds ratio of LBW was 10.6 (95% CI, 9.9–11.4) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was statistically significant heterogeneity ($I^2 = 89\%$, *P*<.01) within the studies included.

Mean birth weight.—A total of 22 studies reported mean birth weight (MBW) for infants, which included one registry study and 21 cohort studies (Fig. 16). Data for mean birth weight were collected. The mean difference in birth weight was 856 grams (\pm -880; -832 grams standard deviation [SD]) lower in IVF-ICSI twin gestations when compared to singleton IVF-ICSI gestation. There was statistically significant heterogeneity (I² = 95%, *P*<.01) within the studies included.

Mean gestational age.—A total of 27 studies reported mean gestational age (MGA): 10 registry studies and 17 cohort studies (Fig. 17). Data for mean gestational age in weeks (SD) was collected. The mean difference in gestational age in weeks was 2.9 (\pm -3.0; –2.8 SD) lower in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. There was statistically significant heterogeneity (I² = 95%, *P*<.01) within the studies included.

Neonatal intensive care unit admission rate.—A total of 11 cohort studies reported outcomes for NICU/SCBU admission rate (Fig. 18). The odds ratio of NICU/SCBU admissions was 6.5 (95% CI, 5.8–7.3) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestation. There was statistically significant heterogeneity ($I^2 = 91\%$, P<.01) within the studies included.

Perinatal mortality rate.—A total of nine studies reported outcomes of perinatal mortality (PNM) rate: seven registry studies and two cohort studies (Fig. 19). Perinatal mortality data in Gunby et al. (17–23) included stillbirth and neonatal deaths whereas, Tandberg et al. (55) defined perinatal mortality as death of the fetus from 22 weeks until 7 days after birth, stillbirths included. The odds ratio of perinatal mortality was 2.4 (95% CI, 2.1–2.8) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestations. Heterogeneity was attributed to chance ($I^2 = 0\%$, *P*=.49) within the studies included.

Stillbirth rate.—A total of eight studies reported outcomes for stillbirth rate: one registry study and seven cohort studies (Fig. 20). The odds ratio (95% CI) of stillbirth rate for at least one of the twins was 2.2(1.8–2.6) in IVF-ICSI twin gestations when compared with singleton IVF-ICSI gestation. There was minimal heterogeneity ($I^2 = 36\%$, *P*=.09) within the studies included.

Studies included in narrative review

Studies with health care cost outcomes.—Chambers et al. (31) combined three national data sets to develop an economic costing model using birth outcomes from 2003.

Data for 5,005 mothers and 5,886 live-born infants were used. After adjusting for maternal age, the average cost (combined for infant and mother) per in-patient birth episode was three times higher for birth episodes of ART twins than ART singletons (14,114 Euros vs. 4,624 Euros). It was estimated that multiple pregnancy reduction strategies would have saved 9.2 million Euros (year 2003–2004 Euros) in birth admission costs alone.

Motohashi et al. (63) performed a costs analysis of maternal and fetal medical care for triplets and higher-order multiples in Japan. The authors examined a control group that included 58 ART singletons and 21 twins born no earlier than 22 weeks of gestation. Data included maternal admissions after 12 weeks of gestation until discharge. It was estimated that the maternal costs (×1,000¥) for singletons was 530 ± 467 compared with $1,124 \pm 709$ in twins. Infant costs (×1,000¥) estimated from birth until discharge from hospital were 173 ± 410 for singleton infants compared with $1,889 \pm 3,061$ for twins (per neonate). The combined cost (×1,000¥) for a family was estimated to be 703 ± 680 for a singleton delivery compared with $4,903 \pm 6,199$ for a twin delivery.

Lemos et al. (65) examined adjusted all-cause health care costs for IVF-ICSI singletons and IVF-ICSI twins in a subgroup analysis. The mean cost in US\$ for an IVF-ICSI singleton infant was 11,358 (95% CI, 10,959–11,772) compared with 81,757 (95% CI, 77,785–85,932) in twins. The mean cost in US\$ for a mother with singleton pregnancy was 15,542 (95% CI, 15,322–15,765) compared with 33,729 (95% CI, 33,066–34,405) a mother with twins. The mean total cost in US\$ for IVF-ICSI singleton pregnancy was 26,922 (95% CI, 10,959–11,772) compared with 115,238 (95% CI, 111,875–118,702) in a twin pregnancy.

Gerris et al. (41) conducted a cost analysis of single-embryo transfer versus a doubleembryo transfer in women undergoing their first IVF-ICSI cycle. In women who had a double-embryo transfer, the costs were analyzed for singleton pregnancies and twin pregnancies. The total cost for antenatal care for mothers was US\$ 5,160 (\pm 4,106 SD) for a singleton pregnancy and US\$ 7,477 (\pm 3,009 SD) for twins. The total cost per infant was US\$ 3,453 (\pm 8,154 SD) for singleton infants and US\$ 12,728 (\pm 12,361 SD) for twins. Maternal hospitalization cost for delivery was US\$ 4,232 (\pm 4,244 SD) for singletons and US\$ 6,814 (\pm 3,029 SD) for twins.

Koivurova et al. (46) performed a 7-year follow-up study of IVF children and analyzed medical diagnoses associated with postneonatal hospital admissions and costs per hospital admission. The Diagnosis Related Groups (DRGS) included brain damage, central nervous system disorder, seizure and headaches, psychiatric disorders, upper respiratory infection, asthma, esophagitis, juvenile rheumatoid arthritis, and prematurity. As the hospital costs were calculated per neonate, the investigators did not find any admission-related cost differences per episode between IVF singletons and IVF twins.

A population cohort study from Western Australia evaluated hospital costs for multiple birth and singleton infants from birth through 5 years of age. In this study, 1.0% of singletons and 15.4% of twins were the result of ART. The mean hospital costs (in US\$) of a singleton or twin child to age 5 years was 2,730 and 8,993, respectively (in 2009–2010 US\$). Most of the

cost increase was seen from birth to 1 year of age mostly due to prematurity. Higher costs for twins were also seen in the second year of life, but in years 3 to 5 the health care costs were similar.

Studies with social outcomes.—Pinborg et al. (40) conducted a national survey using a questionnaire-based study and found that 87.3% of mothers with IVF-ICSI twin were on sick leave compared with 50.1% of mothers with singletons. Sick leave was defined as leave of absence from work owing to illness except for obligatory maternity leave. Mothers with IVF-ICSI twins spend an average of 10.7 weeks on sick leave compared to 8.5 weeks for mothers with singletons (P<.001). The odds ratio for sick leave stratified for maternal age and parity for IVF-ICSI twins versus IVF-ICSI singleton was 6.8 (95% CI, 4.4–10.5).

Olivennes et al. (66) studied in behavioral and cognitive functioning as well as family functioning in 344 families with IVF-ICSI twins compared with 344 families with IVF-ICSI singletons, all between the ages of 2 and 5 years. Using standardized questionnaires and screening tests, they found that mothers of twins showed statistically significantly higher levels of parenting stress and depression than mothers of singletons, and they found parenting to be more difficult and less pleasurable. Frequency of sexual intercourse was also less among couples with twins. In the children there were no differences in emotional or behavioral issues although twins showed statistically significantly lower levels of cognitive functioning.

DISCUSSION

This up-to-date review and meta-analysis comparing maternal, fetal, and societal outcomes for twin pregnancy and singleton pregnancy after IVF-ICSI demonstrates clear evidence for the adverse effects of twin pregnancies. With twin pregnancies, the higher maternal risks, the greatly increased risk of premature delivery for infants, and the higher health care costs that result are consistent among studies throughout the world. The data are compelling that a strategy of one healthy baby at a time should be the objective of every IVF-ICSI treatment cycle.

For women with a twin pregnancy after IVF-ICSI, the most statistically significant risks are higher rates of antenatal hospitalization, preterm labor, need for cesarean delivery, and postpartum hemorrhage. Compared with a singleton pregnancy, twin pregnancies are at higher risk for other complications including gestational diabetes, hypertensive disorders, and placental abruption. Although these latter complications are statistically significantly higher in a given pregnancy event, with odds ratios of less than 2.0 one could argue that a woman who desires at least two children from IVF-ICSI might incur similar risks with two singletons as with a twin pregnancy. We found limited evidence that women with twin gestations required more hospitalizations and more time away from work, and experienced greater stress, more depressive symptoms, and less satisfaction with parenting than mothers of singletons, at least while their children are very young.

Twins after IVF-ICSI are at statistically significantly higher risk for premature delivery, on average 2.9 weeks earlier than singletons leading to a lower average birth weight of 850

grams. For twins, the odds of very preterm birth less than 28 weeks are increased over fivefold and the risk of needing newborn intensive care after delivery is increased over sixfold compared with singletons. The odds of stillbirth and the perinatal mortality rate of twin gestations/newborns are over twofold higher than with singletons.

Health care cost studies have consistently shown that twins after IVF-ICSI are statistically significantly more costly to the health care system than a singleton. Studies that differed by country of origin, currency, time frame, and cost were included in the analysis, which precluded direct comparisons by meta-analysis. Nevertheless, the studies consistently found a twin pregnancy and delivery to be approximately 4.5-fold (range: 2.9- to 6.9-fold) more costly than a singleton pregnancy and delivery. When calculated on a per-baby basis, a twin infant is associated with an approximately 2.5-fold (range: 1.45- to 3.6-fold) increase in health care costs as compared with a singleton.

More studies comparing the early childhood health and development of IVF-ICSI twins compared with singletons are needed. There are limited data of some delay in early childhood growth and development in twins, but the limited data on academic achievement beyond childhood are reassuring.

Spangmose et al. (60) assessed academic performance in a Danish cohort of IVF singletons and IVF twins and concluded that the ART singletons and twins had similarly adjusted mean test scores for Danish, English, and mathematics. Nakajo et al. (67) assessed mental and physical development for 2 years after birth in IVF-ICSI singletons and twins and found no difference in mean physical growth (height and weight) between IVF-ICSI singletons and IVF-ICSI twins. There was also no difference in development related to movements, reactions, and understanding commands (67).

Kuiper et al. (68) studied neurodevelopmental and cardiometabolic outcomes in 4-year-old twins (n = 48) and singletons (n = 103) conceived by IVF. The investigators found similar neurologic outcomes although the total IQ score in twins was slightly lower (-5.4 points) than in singletons. The IVF twins had a lower body weight and were shorter than the singletons, but all other developmental and cardiometabolic parameters were similar (68). Strömberg et al. (69), in a cohort study included children born after IVF aged 18 months or older, and found a 0.7% incidence of cerebral palsy in IVF twins compared with 0.37% in IVF singletons. The increased incidence of cerebral palsy in twins, however, was attributed to low birth weight and prematurity (69).

The limitations of our study includes the inherent limitations of a review of observational studies. The included studies had many fundamental differences, including their retrospective design and nonstandardized data collection. There also were differences in study design and the definition of study variables. Maternal morbidity depends on non-modifiable factors such as age and modifiable factors like body mass index. Fetal morbidity and mortality may be associated with different demographic variables and the cause of infertility in the couple. Studies included in our review did not report outcomes based on maternal age or cause of infertility. This limitation in data collection did not allow us to perform adjustment of confounding factors such as maternal age, sociodemographic aspects,

infertility diagnosis, specifics of IVF treatment protocols, embryo quality, or embryo culture media. However, assessment of maternal and fetal outcomes in oocyte recipient models suggest suboptimal outcomes in twin pregnancies compared with singleton pregnancies. Based on this, we may assume that it is the plurality of pregnancy rather than maternal age that causes suboptimal maternal and fetal outcomes.

Only clinically relevant maternal and fetal outcomes were assessed within the scope of this review. Some manuscripts included in this study contained data for cholestasis during pregnancy, nausea/vomiting, and/or hyperemesis gravidarum. We did not include these subjective symptoms associated with most pregnancies. Further, registry studies had the disadvantage of underreporting (e.g., approximately 7% of clinics in the United States did not report outcome data to SART in 2015). Multiple cohort studies had a smaller sample size and other biases, including treatment bias (the mixed-model of obstetric care: private and state funded health care system), reporting bias, and ascertainment bias. We performed metanalysis of proportions and mean differences when possible for applicable variables in these different studies; nevertheless, there is substantial heterogeneity between studies pooled in the meta-analyses. Finally, this is a descriptive review based on crude outcomes (i.e., outcomes were not based on comparing the intervention of a single-embryo transfer versus a double- or multiple-embryo transfer).

Notwithstanding the limitations, the large number of studies, number of events included in the registry studies, and narrow confidence intervals support the validity of the conclusions in this review. It is imperative that professionals who are working to help patients with infertility build healthy families understand the short- and long-term impacts of their treatment practices. These potentially life-changing impacts are felt by colleagues in obstetrics and pediatrics, by hospital systems and insurers, and most importantly by the patients and their families. To mitigate these risks, work at the level of quality assurance, advocacy, policy and practice change, and patient education must continue.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported in part by the University of Iowa Institute for Clinical and Translational Science, which receives Clinical and Translational Science Award funds from the National Institutes of Health (UL1TR002537).

REFERENCES

- ESHRE Capri Workshop Group. Multiple gestation pregnancy. Hum Reprod 2000;15:1856–64. [PubMed: 10920117]
- Whitford HM, Wallis SK, Dowswell T, West HM, Renfrew MJ. Breastfeeding education and support for women with twins or higher order multiples. Cochrane Database Syst Rev 2017;2:CD012003. [PubMed: 28244065]
- Hamilton BE, Martin JA, Osterman MJK, Curtin SC, Mathews TJ. Births: Final data for 2014. National Vital Statistics Reports; vol 64 no 12. Hyattsville, MD: National Center for Health Statistics. 2015. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_12.pdf. Centers

for Disease Control and Prevention – National Center for Health Statistics. Accessed April 28, 2020.

- Kulkarni AD, Jamieson DJ, Jones HW Jr, Kissin DM, Gallo MF, Macaluso M, Adashi EY. Fertility treatments and multiple births in the United States. N Engl J Med 2013;369:2218–25. [PubMed: 24304051]
- Kissin DM, Kulkarni AD, Kushnir VA, Jamieson DJ. National ART Surveillance System Group. Number of embryos transferred after in vitro fertilization and good perinatal outcome. Obstet Gynecol 2014;123:239–47. [PubMed: 24402601]
- Kissin DM, Kulkarni AD, Mneimneh A, Warner L, Boulet SL, Crawford S, Jamieson DJ. National ART Surveillance System (NASS) Group. Embryo transfer practices and multiple births resulting from assisted reproductive technology: an opportunity for prevention. Fertil Steril 2015;103:954–61. [PubMed: 25637480]
- https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2018 (2018 preliminary data). Accessed April 28, 2020.
- De Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V, et al. European IVF-Monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Hum Reprod 2010;25:1851–62. [PubMed: 20570973]
- 9. De Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V, et al. European IVF-Monitoring (EIM); Consortium for the European Society on Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2007: results generated from European registers by ESHRE. Hum Reprod 2012;27:954–66. [PubMed: 22343707]
- Ferraretti AP, Goossens V, de Mouzon J, Bhattacharya S, Castilla JA, Korsak V, et al. European IVF-Monitoring (EIM), Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2008: results generated from European registers by ESHRE. Hum Reprod 2012;27:2571–84. [PubMed: 22786779]
- Ferraretti AP, Ferraretti V, Goossens M, Kupka S, Bhattacharya J, de Mouzon JA, et al. European IVF-monitoring (EIM), Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE. Hum Reprod 2013;28:2318–31. [PubMed: 23842560]
- Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D'Hooghe T, Castilla JA, et al. European IVF-Monitoring (EIM). Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Hum Reprod 2014;29:2099–113. [PubMed: 25069504]
- Kupka MS, D'Hooghe T, Ferraretti AP, de Mouzon J, Erb K, Castilla JA, et al. European IVF-Monitoring Consortium (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2011: results generated from European registers by ESHRE. Hum Reprod 2016;31:233–48. [PubMed: 26740578]
- Calhaz-Jorge C, de Geyter C, Kupka MS, de Mouzon J, Erb K, Mocanu E, et al. European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. Hum Reprod 2016;31:1638–52. [PubMed: 27496943]
- Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon J, Erb K, Mocanu E, et al. European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE. Hum Reprod 2017;32:1957– 73. [PubMed: 29117383]
- 16. De Geyter Ch, Calhaz-Jorge C, Kupka MS, Wyns C, Mocanu E, Motrenko T, et al. European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). ART in Europe, 2014: results generated from European registries by ESHRE: the European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2018;33:1586–601. [PubMed: 30032255]
- Gunby J, Daya S. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies (ART) in Canada: 2001 results from the Canadian ART Register. Fertil Steril 2005;84:590–9. [PubMed: 16169390]

- Gunby J, Daya S. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies (ART) in Canada: 2002 results from the Canadian ART Register. Fertil Steril 2006;86:1356–64. [PubMed: 17070192]
- Gunby J, Daya S. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies (ART) in Canada: 2003 results from the Canadian ART Register. Fertil Steril 2007;88:550–9. [PubMed: 17303133]
- Gunby J, Bissonnette F, Librach C, Cowan L. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies (ART) in Canada: 2004 results from the Canadian ART Register. Fertil Steril 2008;89:1123–32. [PubMed: 17706210]
- Gunby J, Bissonnette F, Librach C, Cowan L. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register. Fertil Steril 2009;91:1721–30. [PubMed: 18423460]
- Gunby J, Bissonnette F, Librach C, Cowan L. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies (ART) in Canada: 2006 results from the Canadian ART Register. Fertil Steril 2010;93:2189–201. [PubMed: 19439295]
- Gunby J, Bissonnette F, Librach C, Cowan L. IVF Directors Group of the Canadian Fertility and Andrology Society. Assisted reproductive technologies (ART) in Canada: 2007 results from the Canadian ART Register. Fertil Steril 2011;95:542–7.e10. [PubMed: 20656287]
- Zegers-Hochschild F, Schwarze JE, Crosby JA, Musri C, Urbina MT. Latin American Network of Assisted Reproduction (REDLARA). Assisted reproductive techniques in Latin America: the Latin American Registry 2016. Reprod Biomed Online 2019;39:452–60. [PubMed: 31320287]
- Zegers-Hochschild F, Schwarze JE, Crosby JA, Musri C, Urbina MT. Latin American Network of Assisted Reproduction (REDLARA). Assisted reproductive techniques in Latin America: the Latin American Registry 2015. Reprod Biomed Online 2018;37:685–92. [PubMed: 30385145]
- Zegers-Hochschild F, Schwarze JE, Crosby JA, Musri C, Urbina MT. Latin American Network of Assisted Reproduction (REDLARA). Assisted reproductive techniques in Latin America: the Latin American Registry 2014. JBRA Assist Reprod 2017;21:164–75. [PubMed: 28837023]
- Zegers-Hochschild F, Schwarze JE, Crosby JA, Musri C, Urbina MT. Latin American Network of Assisted Reproduction (REDLARA). Assisted reproductive techniques in Latin America: the Latin American Registry 2013. Reprod Biomed Online 2016;32:614–25. [PubMed: 26997476]
- Sunderam S, Kissin DM, Crawford SB, Folger SG, Boulet SL, Warner L, Barfield WD. Assisted Reproductive Technology Surveillance—United States, 2015. MMWR Surveill Summ 2018;67:1– 28.
- Sunderam S, Kissin DM, Crawford SB, Folger SG, Boulet SL, Warner L, Barfield WD. Assisted reproductive technology surveillance—United States, 2014. MMWR Surveill Summ 2017;66:1– 24.
- Sunderam S, Kissin DM, Crawford SB, Folger SG, Boulet SL, Warner L, Barfield WD. Assisted reproductive technology surveillance—United States, 2013. MMWR Surveill Summ 2015;64:1– 25.
- Chambers GM, Chapman MG, Grayson N, Shanahan M, Sullivan EA. Babies born after ART treatment cost more than non-ART babies: a cost analysis of inpatient birth-admission costs of singleton and multiple gestation pregnancies. Hum Reprod 2007;22:3108–15. [PubMed: 17905747]
- Felberbaum RE. Multiple pregnancies after assisted reproduction–international comparison. Reprod Biomed Online 2007;15(Suppl 3):53–60. [PubMed: 18598610]
- Makhseed M, Al-Sharhan M, Egbase P, Al-Essa M, Grudzinskas JG. Maternal and perinatal outcomes of multiple pregnancy following IVF-ET. Int J Gynaecol Obstet 1998;61:155–63. [PubMed: 9639220]
- Callahan TL, Hall JE, Ettner SL, Christiansen CL, Greene MF, Crowley WF Jr. The economic impact of multiple-gestation pregnancies and the contribution of assisted-reproduction techniques to their incidence. N Engl J Med 1994;331:244–9. [PubMed: 8015572]
- Goldfarb JM, Austin C, Lisbona H, Peskin B, Clapp M. Cost-effectiveness of in vitro fertilization. Obstet Gynecol 1996;87:18–21. [PubMed: 8532258]

- 36. Rizk B, Doyle P, Tan SL, Rainsbury P, Betts J, Brinsden P, Edwards R. Perinatal outcome and congenital malformations in in-vitro fertilization babies from the Bourn–Hallam group. Hum Reprod 1991;6:1259–64. [PubMed: 1752928]
- 37. Merritt T, Goldstein M, Philips R, Peverini R, Iwakoshi J, Rodriguez A, Oshiro B. Impact of ART on pregnancies in California: an analysis of maternity outcomes and insights into the added burden of neonatal intensive care. J Perinatol 2014;34:345–50. [PubMed: 24556981]
- Luke B, Brown MB, Wantman E, Seifer DB, Sparks AT, Lin PC, et al. Risk of prematurity and infant morbidity and mortality by maternal fertility status and plurality. J Assist Reprod Genet 2019;36:121–38. [PubMed: 30328574]
- Dhont M, De Sutter P, Ruyssinck G, Martens G, Bekaert A. Perinatal outcome of pregnancies after assisted reproduction: a case-control study. Am J Obstet Gynecol 1999;181:688–95. [PubMed: 10486485]
- 40. Pinborg A, Loft A, Rasmussen S, Schmidt L, Langhoff-Roos J, Greisen G, Andersen AN. Neonatal outcome in a Danish national cohort of 3438 IVF/ICSI and 10 362 non-IVF/ICSI twins born between 1995 and 2000. Hum Reprod 2004;19:435–41. [PubMed: 14747193]
- Gerris J, De Sutter P, De Neubourg D, Van Royen E, Vander Elst J, Mangelschots K, et al. A real-life prospective health economic study of elective single embryo transfer versus two-embryo transfer in first IVF/ICSI cycles. Hum Reprod 2004;19:917–23. [PubMed: 14990547]
- 42. FIVNAT 1996 report. French national register on in vitro fertilization (article in French). Contracept Fertil Sex 1997;25:499–502. [PubMed: 9410352]
- Stoop D, Baumgarten M, Haentjens P, Polyos NP, De Vos M, Verheyen G, et al. Obstetric outcome in donor oocyte pregnancies: a matched-pair analysis. Reprod Biol Endocrinol 2012;10:42. [PubMed: 22672289]
- 44. Han Y, Luo H, Zhang Y. Congenital anomalies in infants conceived by infertile women through assisted reproductive technology: a cohort study 2004–2014. Exp Ther Med 2018;16:3179–85. [PubMed: 30214541]
- 45. Ombelet W, Cadron I, Gerris J, De Sutter P, Bosmans E, Martens G, et al. Obstetric and perinatal outcome of 1655 ICSI and 3974 IVF singleton and 1102 ICSI and 2901 IVF twin births: a comparative analysis. Reprod Biomed Online 2005;11:76–85. [PubMed: 16102293]
- Koivurova S, Hartikainen AL, Gissler M, Hemminki E, Sovio U, Järvelin MR. Neonatal outcome and congenital malformations in children born after in-vitro fertilization. Hum Reprod 2002;17:1391–8. [PubMed: 11980770]
- 47. Van Dorp W, Rietveld AM, Laven JS, van den Heuvel-Eibrink MM, Hukkelhoven CW, Schipper I. Pregnancy outcome of non-anonymous oocyte donation: a case-control study. Eur J Obstet Gynecol Reprod Biol 2014;182:107–12. [PubMed: 25268777]
- Ricciarelli E, Bruna I, Verdú V, Torrelló MJ, Herrer R, Gris JM, et al. Impact of assisted reproduction treatments on Spanish newborns: report of 14,119 pregnancies. J Assist Reprod Genet 2013;30:897–905. [PubMed: 23779097]
- D'Souza SW, Rivlin E, Cadman J, Richards B, Buck P, Lieberman BA. Children conceived by in vitro fertilisation after fresh embryo transfer. Arch Dis Child Fetal Neonatal Ed 1997;76:F70–4. [PubMed: 9135283]
- Farhi A, Reichman B, Boyko V, Mashiach S, Hourvitz A, Margalioth EJ, et al. Congenital malformations in infants conceived following assisted reproductive technology in comparison with spontaneously conceived infants. J Matern Fetal Neonatal Med 2013;26:1171–9. [PubMed: 23451839]
- Goldsmith S, Mcintyre S, Badawi N, Hansen M. Cerebral palsy after assisted reproductive technology: a cohort study. Dev Med Child Neurol 2018;60: 73–80. [PubMed: 28980316]
- 52. Belva F, Henriet S, Van den Abbeel E, Camus M, Devroey P, Van der Elst J, et al. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod 2008;23:2227–38. [PubMed: 18628260]
- Belva F, Bonduelle M, Roelants M, Verheyen G, Van Landuyt L. Neonatal health including congenital malformation risk of 1072 children born after vitrified embryo transfer. Hum Reprod 2016;31:1610–20. [PubMed: 27165622]

- 54. Declercq E, Luke B, Belanoff C, Cabral H, Diop H, Gopal D, et al. Perinatal outcomes associated with assisted reproductive technology: the Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART). Fertil Steril 2015;103:888–95. [PubMed: 25660721]
- Tandberg A, Bjørge T, Nygård O, Børdahl P, Skjaerven R. Trends in incidence and mortality for triplets in Norway 1967–2006: the influence of assisted reproductive technologies. BJOG 2010;117:667–75. [PubMed: 20236102]
- 56. Sullivan EA, Chapman MG, Wang YA, Adamson GD. Population-based study of cesarean section after in vitro fertilization in Australia. Birth 2010; 37:184–91. [PubMed: 20887534]
- Pereira N, Petrini AC, Lekovich JP, Schattman GL, Rosenwaks Z. Comparison of perinatal outcomes following fresh and frozen-thawed blastocyst transfers. Int J Gynaecol Obstet 2016;135:96–100. [PubMed: 27388034]
- 58. Zhu L, Zhang Y, Liu Y, Zhang R, Wu Y, Huang Y, et al. Maternal and live-birth outcomes of pregnancies following assisted reproductive technology: a retrospective cohort study. Sci Rep 2016;6:35141. [PubMed: 27762324]
- Lei LL, Lan YL, Wang SY, Feng W, Zhai ZJ. Perinatal complications and live-birth outcomes following assisted reproductive technology: a retrospective cohort study. Chin Med J (Engl) 2019;132:2408–16. [PubMed: 31634242]
- 60. Spangmose AL, Malchau SS, Henningsen AA, Forman JL, Rasmussen S, Loft A, et al. Academic performance in adolescents aged 15–16 years born after frozen embryo transfer compared with fresh embryo transfer: a nationwide registry–based cohort study. BJOG 2019;126:261–9. [PubMed: 30276983]
- Marino JL, Moore VM, Willson KJ, Rumbold A, Whitrow MJ, Giles LC, Davies MJ. Perinatal outcomes by mode of assisted conception and sub-fertility in an Australian data linkage cohort. PLoS One 2014;9: e80398. [PubMed: 24416127]
- Setti PE, Moioli M, Smeraldi A, Cesaratto E, Menduni F, Livio S, et al. Obstetric outcome and incidence of congenital anomalies in 2351 IVF/ICSI babies. J Assist Reprod Genet 2016;33:711– 7. [PubMed: 27116010]
- 63. Motohashi T, Honda T, Hasegawa M, Uchida T, Kanamoto N, Koizumi K, et al. Costs of maternal and neonatal medical care for triplet and quadruplet pregnancies in Japan. Reprod Med Biol 2004;3:159–64. [PubMed: 29699196]
- 64. Chambers GM, Hoang VP, Lee E, Hansen M, Sullivan EA, Bower C, Chapman M. Hospital costs of multiple-birth and singleton-birth children during the first 5 years of life and the role of assisted reproductive technology. JAMA Pediatr 2014;168:1045–53. [PubMed: 25222633]
- 65. Lemos EV, Zhang D, Van Voorhis BJ, Hu XH. Healthcare expenses associated with multiple vs singleton pregnancies in the United States. Am J Obstet Gynecol 2013;209:586.e1–11. [PubMed: 24238479]
- 66. Olivennes F, Golombok S, Ramogida C, Rust J. Behavioral and cognitive development as well as family functioning of twins conceived by assisted reproduction: findings from a large population study. Fertil Steril 2005;84: 725–33. [PubMed: 16169409]
- Nakajo Y, Fukunaga N, Fuchinoue K, Yagi A, Chiba S, Takeda M, et al. Physical and mental development of children after in vitro fertilization and embryo transfer. Reprod Med Biol 2004;3:63–7. [PubMed: 29699186]
- 68. Kuiper D, Bennema A, la Bastide-van Gemert S, Seggers J, Schendelaar P, Haadsma M, et al. Neurodevelopmental and cardiometabolic outcome in 4-year-old twins and singletons born after IVF. Reprod Biomed Online 2017;34:659–67. [PubMed: 28363462]
- Strömberg B, Dahlquist G, Ericson A, Finnström O, Köster M, Stjernqvist K. Neurological sequelae in children born after in-vitro fertilisation: a population-based study. Lancet 2002;359:461–5. [PubMed: 11853790]




FIGURE 1:

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart for study inclusion and exclusion.

		Twin	Sing	leton					
Study	Events	Total	Events	Total	c	dds Ratio	OR	95%-CI	Weight
Gerris, 2004	7	12	7	33			5.2 [1.3; 21.5]	4.4%
Pinborg, 2004	106	236	122	634			3.4 [[2.5; 4.7]	27.6%
Goldfarb, 1996	5	27	3	36			2.5 [0	0.5; 11.5]	3.8%
FIVNAT Register, 1996	753	2470	933	7650		1	3.2 [[2.8; 3.5]	37.2%
Stoop, 2012 -DO	14	57	30	148			1.3	0.6; 2.6]	12.7%
Stoop, 2012 -AO	16	57	32	148			1.4 [0.7; 2.8]	13.4%
Makhseed, 1998	0	31	1	58 -			0.6 [0	0.0; 15.4]	0.9%
Random effects mode		2890		8707	_		2.6 [1.9; 3.5]	100.0%
Heterogeneity: $I^2 = 52\%$, 1	= 0.0662	, p = 0	1.05		0.1	0.51 2 10			

FIGURE 2:

Antenatal hospitalization.

		Twin	Si	ngleton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Gerris, 2004	4	12	5	33		2.8 [0.6; 13.0]	0.4%
Declercq, 2015	3612	4791	2501	6480	+	4.9	[4.5; 5.3]	6.6%
Stoop, 2012- DO	96	114	74	148		5.3	[2.9; 9.7]	2.0%
Stoop, 2012- AO	78	114	55	148		3.7	[2.2; 6.1]	2.4%
Ombelet, 2005- ICSI	526	1102	369	1655		3.2	[2.7; 3.8]	5.8%
Ombelet, 2005- IVF	1497	2901	946	3974		3.4	[3.1; 3.8]	6.4%
Tandberg, 2010	2793	5341	1998	8501	10 I	3.6	[3.3; 3.8]	6.6%
Pinborg, 2004	137	236	169	634	÷ .	3.8	[2.8; 5.2]	4.1%
Sullivan, 2010	2155	2847	6306	14014		3.8	[3.5; 4.2]	6.5%
van Dorp, 2014 - OD	34	49	45	61		0.8	[0.4; 1.9]	1.2%
van Dorp, 2014 - AO	82	119	103	192		1.9	[1.2; 3.1]	2.7%
D'Souza, 1997	71	128	40	150		3.4	[2.1; 5.7]	2.5%
FIVNAT Register, 1996	1408	2470	1997	7650	+	3.8	[3.4; 4.1]	6.5%
Goldsmith, 2017	683	908	894	1927		3.5	[2.9; 4.2]	5.7%
Chambers, 2007	674	897	1843	4087		3.7	[3.1; 4.3]	5.8%
Dhont, 1999	256	574	646	3048	=	3.0	[2.5; 3.6]	5.6%
Makhseed, 1998	28	31	43	58	+ +	3.3 [0.9; 12.3]	0.5%
Luke, 2019 - AO-Fresh	32527	40406	43936	97852	•	5.1	[4.9; 5.2]	6.8%
Luke, 2019 - AO-FET	6689	8127	14943	27930		4.0	[3.8; 4.3]	6.7%
Luke, 2019 - DO-Fresh	7564	8586	9241	13875	+	3.7	[3.4; 4.0]	6.6%
Luke, 2019 - DO-FET	1570	1801	4068	5965	±.	3.2	[2.7; 3.7]	6.0%
Pereira, 2016 - n FET	26	32	70	186		- 7.2 [2.8; 18.3]	1.0%
Pereira, 2016 - HRT - FET	48	58	104	241		6.3 [3.1; 13.1]	1.5%
Random effects model		81644		198809	\$	3.7	[3.3; 4.1]	100.0%
Heterogeneity: $l^2 = 93\%$, $\tau^2 =$	0.0385,	p < 0.01			0.1 0.5 1 2 10			

FIGURE 3:

Cesarean delivery.

		Twin	Sir	ngleton						
Study	Events	Total	Events	Total		Odds Ra	tio	OR	95%-CI	Weight
Declercq, 2015	474	4791	525	6480		÷		1.2	[1.1; 1.4]	13.9%
Stoop, 2012 -DO	8	114	11	148				0.9	[0.4; 2.4]	0.6%
Stoop, 2012 -AO	6	114	4	148		-		- 2.0	[0.6; 7.3]	0.3%
Zhu, 2016	95	982	214	1659				0.7	[0.6; 0.9]	6.1%
Pinborg, 2004	13	236	26	634				1.4	[0.7; 2.7]	1.1%
Lei, 2019	73	803	115	1453		-	3	1.2	[0.9; 1.6]	4.6%
Makhseed, 1998	5	31	8	58		·	-	1.2	[0.4; 4.0]	0.4%
Luke, 2019 - AO-Fresh	4283	40406	8513	97852		+		1.2	[1.2; 1.3]	23.5%
Luke, 2019 - AO-FET	935	8127	2430	27930		+	E.	1.4	[1.3; 1.5]	19.3%
Luke, 2019 - DO-Fresh	1065	8586	1415	13875		÷		1.2	[1.1; 1.4]	18.8%
Luke, 2019 - DO-FET	234	1801	656	5965		+		1.2	[1.0; 1.4]	11.4%
Random effects mode	-	65991		156202	_			1.2	[1.1; 1.3]	100.0%
Heterogeneity: / ² = 58%, τ	= 0.0055	, p < 0.	01		0.2	0.5 1	2 5			

FIGURE 4:

Gestational diabetes mellitus.

		Twin	Sir	gleton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Zhu, 2016	19	982	22	1659		1.5	[0.8; 2.7]	2.3%
Lei, 2019	14	803	15	1453	- <u>++-</u> -	1.7	[0.8; 3.5]	1.6%
Makhseed, 1998	0	31	4	58 —		0.2	[0.0; 3.7]	0.1%
Luke, 2019 - AO-Fresh	485	40406	881	97852	÷	1.3	[1.2; 1.5]	71.3%
Luke, 2019 - AO-FET	65	8127	168	27930	+	1.3	[1.0; 1.8]	10.7%
Luke, 2019 - DO-Fresh	94	8586	111	13875	+	1.4	[1.0; 1.8]	11.6%
Luke, 2019 - DO-FET	13	1801	42	5965		1.0	[0.5; 1.9]	2.3%
Random effects model		60736		148792	↓	1.3	[1.2; 1.5]	100.0%
Heterogeneity: $l^2 = 0\%$, τ^2	= 0, p = 0	.82			0.1 0.5 2 10			

FIGURE 5:

Antepartum hemorrhage: placental abruption.

		Twin	Sir	ngleton					
Study	Events	Total	Events	Total	Od	ds Ratio	OR	95%-CI	Weight
Zhu, 2016	68	982	118	1659	+	4	1.0	[0.7; 1.3]	15.1%
Lei, 2019	14	803	20	1453	-	-	- 1.3	[0.6; 2.5]	5.2%
Luke, 2019 - AO-Fresh	566	40406	2153	97852	+		0.6	[0.6; 0.7]	27.3%
Luke, 2019 - AO-FET	81	8127	391	27930		-	0.7	[0.6; 0.9]	18.8%
Luke, 2019 - DO-Fresh	137	8586	305	13875		-	0.7	[0.6; 0.9]	21.0%
Luke, 2019 - DO-FET	38	1801	131	5965		-	1.0	[0.7; 1.4]	12.7%
Random effects model		60705		148734		>	0.8	[0.7; 0.9]	100.0%
Heterogeneity: $I^2 = 66\%$, τ^2	2 = 0.0260	p = 0.0	11			1			
					0.5	1 2	2		

FIGURE 6:

Antepartum hemorrhage: placenta previa.

		Twin	Sir	ngleton				
Study	Events	Total I	Events	Total	Odds Ratio	OR	95%-CI	Weight
Declercq, 2015	1183	4791	829	6480	[] [2.2	[2.0; 2.5]	16.1%
Stoop, 2012 - OD	28	114	25	148		1.6	[0.9; 2.9]	2.5%
Stoop, 2012 - AO	8	114	13	148		0.8	[0.3; 2.0]	1.2%
Zhu, 2016	16	125	124	1659		1.8	[1.0; 3.2]	2.9%
Pinborg, 2004	31	236	68	634		1.3	[0.8; 2.0]	4.0%
Makhseed, 1998	5	31	11	58 -		0.8	[0.3; 2.6]	0.7%
Lei, 2019	90	803	138	1453	-m-	1.2	[0.9; 1.6]	7.8%
Luke, 2019 - AO-Fresh	3677	40406	4305	97852	E	2.2	[2.1; 2.3]	18.2%
Luke, 2019 - AO-FET	983	8127	1424	27930		2.6	[2.4; 2.8]	16.7%
Luke, 2019 - DO-Fresh	1597	8586	1263	13875	E	2.3	[2.1; 2.5]	16.9%
Luke, 2019 - DO-FET	285	1801	471	5965	-	2.2	[1.9; 2.6]	13.0%
Random effects mode	I	65134		156202		2.0	[1.9; 2.3]	100.0%
Heterogeneity: / ² = 78%, τ	² = 0.0145	, p < 0.0	1					
					0.5 1 2			

FIGURE 7:

Pregnancy-induced hypertension.

		Twin	Sing	gleton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Stoop, 2012 -DO	5	57	2	148		- 7.0	[1.3; 37.3]	8.6%
Stoop, 2012 - AO	5	57	5	148		2.8	[0.8; 9.9]	11.8%
Zhu, 2016	173	982	85	1659	-	4.0	[3.0; 5.2]	24.4%
Makhseed, 1998	1	31	6	58		0.3	[0.0; 2.5]	5.9%
FIVNAT Register, 1996	195	2470	237	7650		2.7	[2.2; 3.3]	25.0%
Lei, 2019	85	803	148	1453	÷	1.0	[0.8; 1.4]	24.3%
Random effects mode Heterogeneity: $I^2 = 91\%$, 1		4400		11116		2.2	[1.2; 4.1]	100.0%
Therefogeneity. 7 - 5170, 1	0.3043	, p < 0	.01		0.1 0.51 2 10			

FIGURE 8:

Postpartum hemorrhage.

Study	Events	Twin Total	Sing Events	leton Total	Odd	s Ratio	OR	95%-CI	Weight
Stoop, 2012 -DO	34	114	15	148			3.8	[1.9; 7.3]	17.1%
Stoop, 2012 -AO	36	114	25	148			2.3	[1.3; 4.1]	18.1%
Zhu, 2016	733	982	290	1659			+ 13.9	[11.5; 16.8]	21.9%
Makhseed, 1998	14	31	7	58		į	6.0	[2.1; 17.3]	12.6%
Goldfarb, 1996	5	27	3	36	_	-	- 2.5	[0.5; 11.5]	8.5%
Lei, 2019	610	803	262	1453			± 14.4	[11.6; 17.7]	21.8%
Random effects model Heterogeneity: l^2 = 91%, τ^2		2071 , ρ < 0		3502	0.1 0.5	1 2	► 6.3	[3.6; 11.0]	100.0%

FIGURE 9:

Preterm labor.

		Twin	Sing	leton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Stoop, 2012 -DO	18	114	15	148	+=-	1.7	[0.8; 3.5]	12.0%
Stoop, 2012 -AO	10	114	8	148		1.7	[0.6; 4.4]	8.0%
Zhu, 2016	55	982	43	1659		2.2	[1.5; 3.3]	22.6%
Pinborg, 2004	32	236	39	634		2.4	[1.5; 3.9]	19.1%
van Dorp, 2014 - OD	22	49	9	61		- 4.7	[1.9; 11.6]	8.9%
van Dorp, 2014 - AC	15	119	22	192	-	1.1	[0.6; 2.2]	12.8%
Lei, 2019	21	803	31	1453	-	1.2	[0.7; 2.2]	16.7%
Random effects model		2417		4295		1.9	[1.4; 2.6]	100.0%
Heterogeneity: $I^2 = 40\%$, τ	² = 0.0663	, p = 0	.12			1		
				0	.1 0.5 1 2	10		

FIGURE 10: Preeclampsia.

		Twin	Sing	leton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Gunby, 2005	17	958	26	1141		0.8	[0.4; 1.4]	2.2%
Gunby, 2006	32	1228	38	1359		0.9	[0.6; 1.5]	3.6%
Gunby, 2007	41	1378	36	1621	- <u></u> -	1.4	[0.9; 2.1]	4.0%
Gunby, 2008	30	1286	40	1804		1.1	[0.7; 1.7]	3.6%
Gunby, 2009	31	1534	46	1909		0.8	[0.5; 1.3]	3.9%
Gunby, 2010	41	1692	47	2123	- <u>li</u>	1.1	[0.7; 1.7]	4.6%
Gunby, 2011	49	1948	52	2461	- <u>i</u>	1.2	[0.8; 1.8]	5.3%
Ombelet, 2005 - ICSI	35	1102	35	1655		1.5	[0.9; 2.4]	3.6%
Ombelet, 2005 - IVF	81	2901	95	3974		1.2	[0.9; 1.6]	9.1%
Koivurova, 2002	4	103	3	153		2.0	[0.4; 9.2]	0.4%
Rizk, 1991	4	125	14	494		1.1	[0.4; 3.5]	0.6%
Dhont, 1999	37	1148	85	3048		1.2	[0.8; 1.7]	5.3%
van Dorp, 2014 - OD	1	49	2	61		- 0.6	[0.1; 7.0]	0.1%
van Dorp, 2014 - AC	2	119	8	192		0.4	[0.1; 1.9]	0.3%
Ricciarelli, 2013	42	4175	37	5270		1.4	[0.9; 2.2]	4.2%
D'Souza, 1997	3	128	5	150		0.7	[0.2; 3.0]	0.4%
FIVNAT Register, 1996	135	4822	201	7448	+	1.0	[0.8; 1.3]	16.8%
Farhi, 2013 - IVF	36	1621	36	1680		1.0	[0.7; 1.7]	3.8%
Farhi, 2013 - ICSI	82	3095	67	2646		1.0	[0.8; 1.5]	7.7%
Goldsmith, 2017	9	908	10	1927	+ +	- 1.9	[0.8; 4.7]	1.0%
Belva, 2008 - IVF	56	1251	47	1523		1.5	[1.0; 2.2]	5.3%
Belva, 2008 - ICSI	44	1211	46	1476		1.2	[0.8; 1.8]	4.7%
Belva, 2008 - IVF - FET	6	98	6	281	++	3.0	[0.9; 9.5]	0.6%
Belva, 2008 - ICSI - FET	10	155	24	381		1.0	[0.5; 2.2]	1.4%
Belva, 2016 - IVF	46	1698	48	1698		1.0	[0.6; 1.4]	4.9%
Belva, 2016 - FET	24	989	26	989		0.9	[0.5; 1.6]	2.6%
Random effects model		35722		47464		1.1	[1.0; 1.2]	100.0%
Heterogeneity: $l^2 = 0\%$, τ^2	= 0, <i>p</i> = 0.	84			0.1 0.5 1 2	10		

FIGURE 11:

Congenital anomalies.

\geq
Ę
Z
9
2
0
D
õ
Ę.
¥

		Twin	Sir	gleton				
Study	Events		Events	Total	Odds Ratio	OR	95%-CI	Weight
Mouzon, 2010	2792	7105	2594	29811	l ni	6.8	[6.4; 7.2]	2.3%
Mouzon, 2012	3448	9003	3234	35150		6.1	F	2.3%
Ferraretti, 2012	4083	9839	3320	39054	in the second se	7.6		2.3%
Ferraretti, 2013	4730	12128	4309	49527		6.7		2.3%
Kupka, 2014	3799	9521	3522	41433	The second se	7.1		2.3%
Kupka, 2016	5151	12656	4837	54961		7.1		2.3%
Calhaz-Jorge, 2016	4823	12399	5094		ni -	6.3		2.3%
Calhaz-Jorge, 2017	4978	12897	5374				[5.9; 6.5]	2.3%
De Geyter, 2018	6769	17269	7844	80036	E.		[5.7; 6.2]	2.3%
Gunby, 2005	627	958	179	1141	13		[8.3; 12.5]	1.9%
Gunby, 2006	849	1228	202	1359	101	12.8	[10.6; 15.6]	2.0%
Gunby, 2007	909	1378	229	1621		11.8	[9.9; 14.1]	2.0%
Gunby, 2008	860	1286	222	1804		14.4	[12.0; 17.3]	2.0%
Gunby, 2009	1100	1534	330	1909		12.1	[10.3; 14.3]	2.1%
Gunby, 2010	1169	1692	338	2123		11.8	[10.1; 13.8]	2.1%
Gunby, 2011	1315	1948	352	2461	121	12.4	[10.7; 14.4]	2.1%
Gerris, 2004	8	12	1	33		- 64.0	[6.3; 654.0]	0.1%
Declercq, 2015	2568	4774	660	6470			[9.3; 11.3]	2.2%
Spangmose, 2017	494	1930	150	2836			[5.1; 7.5]	2.0%
Stoop, 2012 -DO	74	114	21	148	*		[6.1; 20.4]	0.8%
Stoop, 2012 - AO	65	114	18	148			[5.2; 17.8]	0.8%
Ombelet, 2005 - ICSI	641	1102	152	1655			[11.2; 16.9]	1.9%
Ombelet, 2005 - IVF	1654	2901	493	3974	ļ.		[8.3; 10.6]	2.2%
Koivurova, 2002	45	103	13	153	+		[4.2; 16.6]	0.7%
Pinborg, 2004	91	236	98	634			[2.4; 4.8]	1.5%
Zegers-Hochschild, 2019		5727	2045	11959	2		[8.6; 9.9]	2.3%
Zegers-Hochschild, 2018		6326	2011	11627	<u>ė</u>		[8.2; 9.5]	2.3%
Sunderam, 2018	7269	11649	6390	47685			[10.2; 11.2]	2.3%
Zegers-Hochschild, 2017	3520	6398	1865	11373	<u> </u>		[5.8; 6.7]	2.3%
Sunderam, 2017	7765	12484	5748	43544	in the second se		[10.3; 11.3]	2.3%
Zegers-Hochschild, 2016		2623	630	8385			[6.3; 7.9]	2.2%
Sunderam, 2015 Felberbaum, 2007	15010 6974	24607 13335	4920 2379	36996 23551	104		[9.8; 10.6]	2.3%
Makhseed, 1998	20	31	2379	23551			[9.2; 10.3]	0.4%
Callahan, 1994	760	1135	2877	11986			[5.6; 7.3]	2.2%
Rizk, 1991	73	125	69	494	1		[5.6; 13.4]	1.2%
Sullivan, 2010	1045	2847	1292	13894			[5.1; 6.2]	2.2%
Ricciarelli, 2013	1192	2337	634	5280		7.6		2.2%
D'Souza, 1997	57	128	19	150			[3.1; 10.0]	0.8%
FIVNAT Register, 1996	2069	4822	693	7448			[6.6; 8.1]	2.2%
Farhi, 2013 - IVF	997	1621	282	1680	i.		[6.7; 9.3]	2.1%
Farhi, 2013 - ICSI	1903	3095	381	2646			[8.3; 10.8]	2.2%
Marino, 2014 - IVF	252	543	99	948			[5.7; 9.7]	1.7%
Marino, 2014 - ICSI	160	380	57	693			[5.8; 11.4]	1.5%
Marino, 2014 - IVF - FET	58	147	42	448	*		[4.0; 10.0]	1.1%
Marino, 2014 - ICSI - FET		65	11	218			[5.7; 27.5]	0.5%
Goldsmith, 2017	448	908	209	1927	<u>.</u>		[6.6; 9.7]	2.0%
Belva, 2016 - IVF	269	464	131	1374		13.1	[10.1; 16.9]	1.7%
Belva, 2016 - FET	137	234	84	827		12.5	[8.9; 17.6]	1.4%
Luke, 2019 - AO-Fresh	18061	40406		97852	in in	8.0	[7.7; 8.2]	2.3%
Luke, 2019 - AO-FET	3682	8127	2430	27930	ļi.	8.7		2.3%
Luke, 2019 - DO-Fresh	4138	8586	1679	13875	10 I		[6.3; 7.2]	2.3%
Luke, 2019 - DO-FET	895	1801	793	5965		6.4	[5.7; 7.3]	2.2%
Random effects model		285078		863038	i	8.3	[7.8; 8.9]	100.0%
Heterogeneity: $l^2 = 97\%$, τ^2						0.0		
	0.0401,	v = 0.01			0.01 0.1 1 10 100			

FIGURE 12: Preterm birth rate.

		Twin	Sir	ngleton					
Study	Events	Total	Events	Total	Odds Ratio	OR	98	5%-CI	Weight
Mouzon, 2010	185	7105	238	29811	10	3.3	[2.7;	4.0]	6.1%
Mouzon, 2012	288	9003	352	35150		3.3	[2.8;	3.8]	6.5%
Ferraretti, 2012	315	9839	312	39054		4.1	[3.5;	4.8]	6.5%
Ferraretti, 2013	364	12128	446	49527	i di	3.4	[3.0;	3.9]	6.7%
Kupka, 2014	314	9521	456	41433		3.1	[2.6;	3.5]	6.6%
Kupka, 2016	468	12656	495	54961		4.2	[3.7;	4.8]	6.8%
Calhaz-Jorge, 2016	446	12399	554	55370		3.7	[3.3;	4.2]	6.8%
Calhaz-Jorge, 2017	374	12897	759	58414	4	2.3	[2.0;	2.6]	6.8%
De Geyter, 2018	587	17269	720	80036		3.9	[3.5;	4.3]	7.0%
Zegers-Hochschild, 2019	142	5727	99	11959	÷.	3.0	[2.4;	3.9]	5.4%
Zegers-Hochschild, 2018	154	6326	92	11627	10	3.1	[2.4;	4.1]	5.4%
Zegers-Hochschild, 2017	138	6398	0	11373	· · · ·	- 503.2	[31.3; 80	87.1]	0.2%
Zegers-Hochschild, 2016	187	2623	155	8385	(iii)	4.1	[3.3;	5.1]	5.9%
Luke, 2019 - AO-Fresh	1333	40406	685	97852		4.8	[4.4;	5.3]	7.1%
Luke, 2019 - AO-FET	252	8127	223	27930		4.0	[3.3;	4.8]	6.3%
Luke, 2019 - DO-Fresh	215	8586	111	13875	4	3.2	[2.5;	4.0]	5.7%
Luke, 2019 - DO-FET	54	1801	66	5965	-	2.8	[1.9;	4.0]	4.3%
Random effects model		182811		632722		3.5	[3.1;	3.9]	100.0%
Heterogeneity: $l^2 = 88\%$, τ^2	= 0.0462,	p < 0.0	1		0.001 0.1 1 10 100	D			

FIGURE 13: Early preterm birth rate.

		Twin	Sir	gleton					
Study	Events	Total	Events	Total	Odds Ratio	OR	9	5%-CI	Weight
Mouzon, 2010	782	7105	745	29811	1.0	4.8	[4.3;	5.4]	4.5%
Mouzon, 2012	999	9003	949	35150		4.5	[4.1;	4.9]	4.6%
Ferraretti, 2012	984	9839	742	39054		5.7	[5.2;	6.3]	4.6%
Ferraretti, 2013	1152	12128	891	49527		5.7	[5.2;	6.3]	4.6%
Kupka, 2014	990	9521	994	41433	10	4.7	[4.3;	5.2]	4.6%
Kupka, 2016	1316	12656	1264	54961	1	4.9	[4.6;	5.3]	4.7%
Calhaz-Jorge, 2016	1240	12399	1163	55370		5.2	[4.8;	5.6]	4.7%
Calhaz-Jorge, 2017	1187	12897	1402	58414		4.1	[3.8;	4.5]	4.7%
De Geyter, 2018	1848	17269	1841	80036		5.1	[4.8;	5.4]	4.8%
Gunby, 2005	274	958	62	1141	÷	7.0	[5.2;	9.3]	2.6%
Gunby, 2006	292	1228	57	1359	÷	7.1	[5.3;	9.6]	2.6%
Gunby, 2007	333	1378	63	1621	±.	7.9	[6.0;	10.4]	2.7%
Gunby, 2008	296	1286	72	1804		7.2	[5.5;	9.4]	2.8%
Gunby, 2009	348	1534	90	1909	<u>i</u>	5.9	[4.7;	7.6]	3.1%
Gunby, 2010	355	1692	98	2123		5.5	[4.3;	6.9]	3.2%
Gunby, 2011	220	1948	57	2461		5.4	[4.0;	7.2]	2.6%
Declercq, 2015	425	4774	110	6470	<u>i</u>	5.7	[4.6;	7.0]	3.4%
Spangmose, 2017	21	495	20	2836	÷	6.2	[3.4;	11.6]	1.0%
Stoop, 2012 -DO	7	57	4	148		5.0	[1.4;	17.9]	0.3%
Stoop, 2012 -AO	10	57	4	148	*	7.7	[2.3;	25.6]	0.3%
Ombelet, 2005 - ICSI	97	1102	26	1655	÷	6.0	[3.9;	9.4]	1.6%
Ombelet, 2005 - IVF	247	2901	76	3974		4.8	[3.7;	6.2]	2.9%
Koivurova, 2002	44	103	11	153		9.6	[4.7;	19.9]	0.7%
Pinborg, 2004	32	236	16	634	+	6.1	[3.3;	11.3]	1.0%
D'Souza, 1997	17	128	4	150		5.6	[1.8;	17.1]	0.3%
FIVNAT Register, 1996	246	4822	89	7448	- H	4.4	[3.5;	5.7]	3.0%
Marino, 2014 - IVF	61	543	33	948	+	3.5	[2.3;	5.4]	1.6%
Marino, 2014 - ICSI	43	380	8	693	-	10.9	[5.1;	23.5]	0.7%
Marino, 2014 - IVF -FET	22	147	8	448	÷	9.7	-	22.3]	0.6%
Marino, 2014 - ICSI -FET	8	65	0	218		- 64.6	[3.7; 1		0.1%
Goldsmith, 2017	105	908	47	1927	÷	5.2	[3.7;	7.5]	2.1%
Belva, 2016 - IVF	60	464	18	1374	-	11.2	[6.5;	19.2]	1.2%
Belva, 2016 - FET	18	234	15	827	-	4.5	[2.2;	9.1]	0.8%
Luke, 2019 - AO-Fresh	4243	40406	1761	97852		6.4	[6.0;	-	4.9%
Luke, 2019 - AO-FET	886	8127	447	27930	10	7.5	[6.7;	-	4.4%
Luke, 2019 - DO-Fresh	1013	8586	347	13875		5.2	[4.6;	-	4.3%
Luke, 2019 - DO-FET	209	1801	167	5965		4.6	[3.7;	5.6]	3.4%
Random effects model		189177		631847		5.5	[5.2;	5.9]	100.0%
Heterogeneity: $l^2 = 82\%$, τ^2	$^{2} = 0.0238$	n < 0.01							

FIGURE 14:

Very preterm birth rate.

		Twin	Sin	gleton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Gunby, 2005	301	958	35	1141	-	14.5	[10.1; 20.8]	1.9%
Gunby, 2006	227	1228	38	1359	±	7.9	[5.5; 11.2]	1.9%
Gunby, 2007	238	1378	39	1621	- 4	8.5	[6.0; 12.0]	2.0%
Gunby, 2008	233	1286	55	1804	+	7.0	[5.2; 9.5]	2.3%
Gunby, 2009	290	1534	65	1909	=	6.6	[5.0; 8.7]	2.4%
Gunby, 2010	291	1692	68	2123	Ξ	6.3	[4.8; 8.2]	2.5%
Gunby, 2011	520	1948	126	2461	+	6.7	[5.5; 8.3]	3.0%
Gerris, 2004	6	12	1	33		- 32.0	[3.2; 315.9]	0.1%
Declercq, 2015	2401	4774	505	6470		12.0	[10.7; 13.3]	3.8%
Spangmose, 2017	836	1930	199	2836		10.1	[8.5; 12.0]	3.3%
Stoop, 2012 - DO	77	114	13	148		21.6	[10.8; 43.1]	0.8%
Stoop, 2012 - DO	64	114	14	148	+	12.3	[6.3; 23.8]	0.8%
Zhu, 2016	575	982	169	1659		12.5	[10.2; 15.3]	3.0%
Ombelet, 2005 - ICSI	652	1102	131	1655	+	16.9	[13.6; 20.9]	2.9%
Ombelet, 2005 - IVF	1674	2901	382	3974		12.8	[11.3; 14.6]	3.6%
Koivurova, 2002	46	103	6	153		19.8	[8.0; 48.8]	0.5%
Pinborg, 2004	74	236	44	634	+	6.1	[4.1; 9.2]	1.6%
Sunderam, 2018	6384	11649	4149	47685		12.7	[12.1; 13.4]	4.1%
Sunderam, 2017	6891	12484	3875	43544		12.6	[12.0; 13.2]	4.1%
Sunderam, 2015	13854	24607	3330	36996		13.0	[12.5; 13.6]	4.1%
Chambers, 2007	889	1774	328	4050		11.4	[9.8; 13.2]	3.5%
FIVNAT Register, 1996	2744	4822	797	7448	2	11.0	[10.0; 12.1]	3.9%
Marino, 2014 - IVF	316	543	133	948		8.5	[6.6; 11.0]	2.7%
Marino, 2014 - ICSI	211	380	66	693	÷	11.9	[8.6; 16.4]	2.1%
Marino, 2014 - IVF - FET	68	147	33	448	+	10.8	[6.7; 17.5]	1.3%
Marino, 2014 - ICSI - FET	28	65	8	218			[8.4; 46.9]	
Goldsmith, 2017	409	908	135	1927	÷		[8.7; 13.5]	
Belva, 2008 - IVF	564	1251	120	1523			[7.7; 11.9]	
Belva, 2008 - ICSI	582	1211	106	1476			[9.5; 15.0]	
Belva, 2008 - IVF - FET	49	98	20	281	-		[7.1; 23.8]	
Belva, 2008 - ICSI - FET	70	155	24	381	- 1 -		[7.3; 20.6]	
Belva, 2008 - IVF	285	464	110	1374	±		[14.0; 24.0]	
Belva, 2016 - IVF - FET	115	234	57	827			[9.0; 18.9]	
Lei, 2019	401	803	320	1453			[2.9; 4.3]	
Makhseed, 1998	18	31	7	58			[3.5; 29.2]	
Rizk, 1991	118	262	53	527	1		[5.0; 10.7]	
Luke, 2019 - AO-Fresh	22587	40406	8807	97852	1		[12.4; 13.2]	
Luke, 2019 - AO-FET	3982	8127	1899	27930	1		[12.4; 14.0]	
Luke, 2019 - DO-Fresh	4877	8586	1485	13875	11 III		[10.2; 11.8]	
Luke, 2019 - DO- FET	1003	1801	668	5965			[8.8; 11.3]	
Pereira, 2016 - n FET	8	32	7	186			[2.8; 25.6]	
Pereira, 2016 - HRT - FET	14	58	8	241		9.3	[3.7; 23.4]	0.5%
Random effects model		143190		328034	, i	10.6	[9.9; 11.4]	100.0%
Heterogeneity: l^2 = 89%, τ^2 =	= 0.0285, p	< 0.01						
					0.01 0.1 1 10 100			

FIGURE 15:

Low birth weight.

		Twin		Singleton				
Study	Total	Mean SD	Total	Mean SD	Mean Difference	MD	95%-CI	Weight
Gerris, 2004	12	2501 648	33	3357 442	<u> </u>	-856 [-1	252; -460]	0.3%
Declercq, 2015	4774	2440 615	6470	3311 606	<u>i</u>	-871 [-	894; -848]	4.1%
Stoop, 2012 - DO	114	2321 504	148	3211 593	+	-890 [-1	023; -757]	1.9%
Stoop, 2012 - DO	114	2294 524	148	3183 583	+	-889 [-1	023; -755]	1.8%
Ombelet, 2005 - ICSI	1102	2317 591	1655	3227 585		-910 [-	955; -865]	3.7%
Ombelet, 2005 - IVF	2901	2339 580	3974	3193 610	til i la	-854 [-	882; -826]	4.0%
Tandberg, 2010	5341	2525 639	8501	3440 647	D.	-915 [-	937; -893]	4.1%
Pinborg, 2004	236	2509 659	634	3387 638	*	-878 [-	976; -780]	2.5%
Zegers-Hochschild, 2019	5727	2254 515	11959	3055 550		-801 [-	818; -784]	4.2%
Felberbaum, 2007	13335	2430 .	23551	3320 .		-890		0.0%
Makhseed, 1998	31	2380 483	58	3086 756		-706 [-	964; -448]	0.7%
Rizk, 1991	125	2389 .	494	3124 .	1	-735		0.0%
Merritt, 2014	1713	2170 355	3997	2866 210	4	-696 [-	714; -678]	4.2%
Dhont, 1999	574	2377 553	3048	3172 614			845; -745]	3.6%
van Dorp, 2014 -OD	49	2320 .	61	3375 .		-1055		0.0%
van Dorp, 2014 -AC	119	2500 .	192	3195 .	1	-695		0.0%
Setti, 2016	796	2228 534	1426	3078 609	in a second seco	-850 [-	899; -801]	3.6%
D'Souza, 1997	128	2078 612	150	3016 641		-938 [-1	086; -790]	1.6%
Farhi, 2013 - IVF	1621	2243 653	1680	3092 616	<u>.</u>	-849 [-	892; -806]	3.8%
Farhi, 2013 - ICSI	3095	2244 617	2646	3105 599	i i i i i i i i i i i i i i i i i i i	-861 [-	893; -829]	4.0%
Marino, 2014 - IVF	543	2274 608	948	3119 697	÷	-845 [-	913; -777]	3.2%
Marino, 2014 - ICSI	380	2332 653	693	3220 589	÷	-888 [-	967; -809]	2.9%
Marino, 2014 - IVF - FET	147	2368 653	448	3375 647	-	-1007 [-1	128; -886]	2.1%
Marino, 2014 - ICSI - FET	65	2523 580	218	3459 491		-936 [-1	091; -781]	1.5%
Goldsmith, 2017	908	2352 595	1927	3212 620	<u>.</u>	-860 [-	908; -812]	3.7%
Belva, 2008 - IVF	1251	2382 560	1523	3176 582		-794 [-	837; -751]	3.8%
Belva, 2008 - IVF - FET	98	2365 623	281	3269 535	-	-904 [-1	042; -766]	1.8%
Belva, 2008 - ICSI	1211	2394 522	1476	3224 581	di la constante di la constant	-830 [-	872; -788]	3.8%
Belva, 2008 - ICSI - FET	155	2505 533	381	3301 571		-796 [-	898; -694]	2.4%
Belva, 2016 - IVF	464	2305 592	1374	3243 558	H	-938 [-	999; -877]	3.4%
Belva, 2016 - IVF - FET	234	2466 515	827	3310 579	*	-844 [-	921; -767]	3.0%
Luke, 2019 - AO-Fresh	40406	2354 424	97852	3237 602	Di la constante de la constante	-883 [-	889; -877]	4.3%
Luke, 2019 - AO-FET	8127	2439 430	27930	3377 615		-938 [-	950; -926]	4.2%
Luke, 2019 - DO-Fresh	8586	2356 411	13875	3243 643		-887 [-	901; -873]	4.2%
Luke, 2019 - DO-FET	1801	2360 423	5965	3235 666	D.	-875 [-	901; -849]	4.1%
Pereira, 2016 - n FET	32	2638 426	186	3327 626		-689 [-	862; -516]	1.3%
Pereira, 2016 - HRT - FET	58	2647 418	241	3333 497	-	-686 [-	811; -561]	2.0%
Random effects model			226970			-856 [-	880; -832]	100.0%
Heterogeneity: $l^2 = 95\%$, $\tau^2 =$	3521.452	6, p < 0.01						
The second s					-1000-500 0 500 100	00		

FIGURE 16:

Mean birth weight.

		Twin		Singleton					
Study	Total	Mean SD	Total	Mean SD	Mean Diffe	rence	MD	95%-CI	Weight
Gunby, 2005	958	36.0 3.0	1141	39.0 3.0	÷ [-3.0	-3.3; -2.7]	3.6%
Gunby, 2006	1228	36.0 3.0	1359	39.0 3.0	10-10-10-10-10-		-3.0	-3.2; -2.8]	3.7%
Gunby, 2007	1378	36.0 3.0	1621	39.0 3.0	E			-3.2; -2.8]	
Gunby, 2008	1286	36.0 3.0	1804	39.0 3.0	1		-3.0	-3.2; -2.8]	3.8%
Gunby, 2009	1534	36.0 3.0	1909	39.0 3.0			-3.0	-3.2; -2.8]	3.9%
Gunby, 2010	1692	36.0 3.0	2123	39.0 3.0	E			-3.2; -2.8]	
Gunby, 2011	1948	36.0 3.0	2461	39.0 3.0	10 A		-3.0	-3.2; -2.8]	3.9%
Gerris, 2004	12	35.9 2.3	33	39.3 1.2			-3.4	-4.8; -2.0]	0.7%
Declercq, 2015	4774	35.6 3.0	6470	38.6 2.2			-3.0	-3.1; -2.9]	4.2%
Stoop, 2012 - DO	114	35.4 2.9	148	38.7 2.3			-3.3	-3.9; -2.7]	1.9%
Stoop, 2012 - AO	114	35.4 2.8	148	38.7 2.0	- <u>m:</u>		-3.3	-3.9; -2.7]	2.0%
Ombelet, 2005 - ICSI	1102	35.4 3.0	1655	38.6 2.2	12		-3.2	-3.4; -3.0]	3.8%
Ombelet, 2005 - IVF	2901	35.0 3.0	3974	38.4 2.2			-3.4	-3.5; -3.3]	4.1%
Tandberg, 2010	5341	36.0 3.2	8501	39.1 2.3	÷.		-3.1	-3.2; -3.0]	4.2%
Pinborg, 2004	236	33.1 3.5	634	34.1 3.5			-1.0	-1.5; -0.5]	2.4%
Zegers-Hochschild, 2019	5727	35.1 2.8	11959	37.7 2.2			-2.6	-2.7; -2.5]	4.2%
Zegers-Hochschild, 2018	6326	35.2 2.7	11627	37.6 2.2			-2.4	-2.5; -2.3]	4.2%
Zegers-Hochschild, 2017	2623	35.2 .	8385	37.5 .	1.		-2.3		0.0%
Felberbaum, 2007	13335	36.0 .	23551	39.0 .			-3.0		0.0%
Makhseed, 1998	31	35.8 1.8	58	37.1 2.5	<u> </u>		-1.3 [[-2.2; -0.4]	1.2%
Rizk, 1991	125	36.0 .	494	38.7 .			-2.7		0.0%
Merritt, 2014	1713	34.1 4.1	3997	36.0 2.1			-1.9 [[-2.1; -1.7]	3.8%
Dhont, 1999	574	36.1 2.8	3048	38.5 2.2	H		-2.4 [[-2.6; -2.2]	3.7%
van Dorp, 2014 - OD	49	36.0 .	61	39.0 .			-3.0		0.0%
van Dorp, 2014 - AO	119	36.0 .	192	39.0 .			-3.0		0.0%
Setti, 2016	796	35.5 2.6	1426	38.6 2.3			-3.1 [-3.3; -2.9]	3.8%
D'Souza, 1997	128	35.2 3.1	150	38.4 2.5			-3.2 [-3.8; -2.5]	1.9%
Goldsmith, 2017	908	35.0 3.0	1927	38.0 2.5	10 I		-3.0	-3.2; -2.8]	3.8%
Belva, 2016 - IVF	464	35.4 3.0	1374	38.8 2.0	-		-3.4 [-3.7; -3.1]	3.4%
Belva, 2016 - FET	234	35.7 2.5	827	38.7 2.1	÷		-3.0 [[-3.4; -2.6]	3.2%
Luke, 2019 - AO -Fresh	40406	35.3 3.0	97852	38.4 2.2	÷.		-3.1 [[-3.1; -3.1]	4.3%
Luke, 2019 - AO -FET	8127	35.3 3.0	27930	38.4 2.2			-3.1 [[-3.2; -3.0]	4.3%
Luke, 2019 - DO -Fresh	8586	35.2 2.9	13875	38.2 2.4	IC.		-3.0 [[-3.1; -2.9]	4.3%
Luke, 2019 - DO -FET	1801	35.1 2.9	5965	38.0 2.5			-2.9 [[-3.0; -2.8]	4.1%
Random effects model	116690		248679		6		-2.9 [-3.0; -2.8]	100.0%
Heterogeneity: $l^2 = 95\%$, τ^2	= 0.0863	p < 0.01							
					-4 -2 0	2 4	l.		

FIGURE 17:

Mean gestational age.

		Twin	Sir	gleton				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Gerris, 2004	6	12	1	33	1 +++	32.0	[3.2; 315.9]	0.2%
Ombelet, 2005 - ICSI	743	1102	323	1655		8.5	[7.2; 10.2]	7.1%
Ombelet, 2005 - IVF	2025	2901	858	3974		8.4	[7.5; 9.4]	8.0%
Koivurova, 2002	39	103	21	153		3.8	[2.1; 7.0]	2.4%
Makhseed, 1998	10	31	6	58		4.1	[1.3; 12.8]	0.8%
Goldfarb, 1996	6	27	0	36		- 22.1	[1.2; 411.4]	0.1%
Callahan, 1994	545	1135	1798	11986		5.2	[4.6; 5.9]	7.7%
Dhont, 1999	784	1148	637	3048	in the second seco	8.2	[7.0; 9.5]	7.4%
Belva, 2008 - IVF	847	1251	285	1523		9.1	[7.6; 10.8]	7.1%
Belva, 2008 - ICSI	768	1211	258	1476	-	8.2	[6.8; 9.8]	7.0%
Belva, 2008 - IVF - FET	68	98	65	281		7.5	[4.5; 12.6]	3.0%
Belva, 2008 - ICSI - FET	88	155	77	381	+	5.2	[3.5; 7.8]	4.0%
Belva, 2016 - IVF	268	464	183	1374		8.9	[7.0; 11.3]	6.1%
Belva, 2016 - FET	124	234	119	827	÷	6.7	[4.9; 9.3]	4.9%
Makhseed, 1998	21	62	6	58		4.4	[1.6; 12.0]	1.1%
Luke, 2019 - AO-Fresh	13132	40406	7730	97852	10	5.6	[5.4; 5.8]	8.6%
Luke, 2019 - AO-FET	2625	8127	2318	27930		5.3	[4.9; 5.6]	8.4%
Luke, 2019 - DO-Fresh	3100	8586	1457	13875		4.8	[4.5; 5.2]	8.3%
Luke, 2019 - DO-FET	648	1801	620	5965	*	4.8	[4.3; 5.5]	7.7%
Random effects model		68854		172485		6.5	[5.8: 7.3]	100.0%

FIGURE 18:

Neonatal intensive care unit admission rate.

		Twin	Sing	leton				
Study	Events	Total E	vents	Total	Odds Ratio	OR	95%-CI	Weight
Gunby, 2005	35	958	26	1141		1.6	[1.0; 2.7]	7.4%
Gunby, 2006	49	1228	18	1359	n	- 3.1	[1.8; 5.3]	6.6%
Gunby, 2007	50	1378	18	1621		- 3.4	[1.9; 5.8]	6.6%
Gunby, 2008	46	1286	23	1804		2.9	[1.7; 4.8]	7.7%
Gunby, 2009	41	1534	32	1909		1.6	[1.0; 2.6]	9.0%
Gunby, 2010	51	1692	25	2123		2.6	[1.6; 4.2]	8.4%
Gunby, 2011	62	1948	32	2461		2.5	[1.6; 3.8]	10.6%
Ombelet, 2005 - ICSI	34	1102	20	1655		2.6	[1.5; 4.5]	6.3%
Ombelet, 2005 - IVF	70	2901	44	3974	<u> </u>	2.2	[1.5; 3.2]	13.6%
Tandberg, 2010	123	5341	77	8501		2.6	[1.9; 3.4]	23.8%
Random effects mode		19368		26548		2.4	[2.1; 2.8]	100.0%
Heterogeneity: $l^2 = 0\%$, τ^2	= 0, p = 0.	49		Г		1		
				0.2	0.5 1 2	5		

FIGURE 19:

Perinatal mortality rate.

Author Manuscript

Author Manuscript

		Twin	Sing	gleton				
Study	Events	Total E	vents	Total	Odds Ratio	OR	95%-CI	Weight
Ombelet, 2005 - ICSI	23	1102	13	1655		2.7	[1.4; 5.3]	6.3%
Ombelet, 2005 - IVF	30	2901	31	3974		1.3	[0.8; 2.2]	9.7%
Callahan, 1994	68	1135	312	11986	÷.	2.4	[1.8; 3.1]	18.2%
Dhont, 1999	7	574	30	3048		1.2	[0.5; 2.8]	4.6%
Ricciarelli, 2013	33	2337	34	5280	- + -	2.2	[1.4; 3.6]	10.3%
FIVNAT Register, 1996	651	4822	462	7448	<u>i</u>	2.4	[2.1; 2.7]	25.2%
Marino, 2014 - IVF	15	558	13	961	<u> </u>	2.0	[1.0; 4.3]	5.4%
Marino, 2014 - ICSI	6	386	10	703		1.1	[0.4; 3.0]	3.2%
Marino, 2014 - IVF - FET	3	150	6	454		1.5	[0.4; 6.2]	1.8%
Marino, 2014 - ICSI - FET	0	65	2	220		0.7	[0.0; 14.1]	0.4%
Belva, 2008 - IVF	34	1251	6	1523		7.1	[3.0; 16.9]	4.2%
Belva, 2008 - ICSI	31	1211	18	1476	- <u>+</u> -	2.1	[1.2; 3.8]	7.9%
Belva, 2008 - IVF - FET	2	98	5	281		1.1	[0.2; 6.0]	1.3%
Belva, 2008 - ICSI - FET	7	155	2	381	+ +	- 9.0	[1.8; 43.6]	1.4%
Random effects model		16745		39390	÷.	2.2	[1.8; 2.6]	100.0%
Heterogeneity: $l^2 = 36\%$, τ^2	= 0.0350,	p = 0.09			0.1 0.51 2 10			

FIGURE 20:

Stillbirth rate.

ist of studies with mat	ernal and fetal out	comes ass	List of studies with maternal and fetal outcomes associated with multiple pregnancies after in vitro fertilization/intracytoplasmic sperm injection.	cies after in vitro fertiliz	ation/intracytoplasmic	sperm injection.
Author, year (ref), geographical area	Study design	Study period	Study characteristics	Data collection and adjustments	Outcome variables of interest	Comments
Mouzon et al., 2010 (8), Europe	Multinational registry	2006	32 European countries, 998 clinics, 458,759 ART cycles; IVF-ICSI singletons: 29,811; IVF-ICSI twins: 7,105	Data from 17 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Mouzon et al., 2012 (9), Europe	Multinational registry	2007	33 European countries, 1,029 clinics, 493,184 ART cycles; IVF- ICSI singletons: 35,150; IVF-ICSI twins: 9,003	Data from 15 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Ferraretti et al., 2012 (10), Europe	Multinational registry	2008	36 European countries, 1,051 clinics, 552,260 ART cycles; IVF- ICSI singletons: 39,054; IVF-ICSI twins: 9,839	Data from 17 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Ferraretti et al., 2013 (11), Europe	Multinational registry	2009	34 European countries, 1,005 clinics, 537,463 ART cycles; IVF- ICSI singletons: 49,527; IVF-ICSI twins: 12,128	Data from 19 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Kupka et al., 2014 (12), Europe	Multinational registry	2010	31 European countries, 991 clinics, 550,296 ART cycles; IVF-ICSI singletons: 41,433; IVF-ICSI twins: 9,521	Data from 18 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Kupka et al., 2016 (13), Europe	Multinational registry	2011	33 European countries, 1,064 clinics, 609,973 ART cycles; IVF- ICSI singletons: 54,961; IVF-ICSI twins: 12,656	Data from 17 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Calhaz-Jorge et al., 2016 (14), Europe	Multinational registry	2012	34 European countries, 1,111 clinics, 640,144 ART cycles; IVF- ICSI singletons: 55,370; IVF-ICSI twins: 12,399	Data from 19 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Calhaz-Jorge et al., 2017 (15), Europe	Multinational registry	2013	38 European countries, 1,169 clinics, 686,271 ART cycles; IVF- ICSI singletons: 58,414; IVF-ICSI twins: 12,897	Data from 18 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
De Geyter et al., 2018 (16), Europe	Multinational registry	2014	39 European countries, 1,279 clinics, 776,556 ART cycles; IVF- ICSI singletons: 80,036; IVF-ICSI twins: 17,269	Data from 20 countries, unadjusted data, combined for autologous and donor cycles	EPTBR (<28 wk), VPTBR (<32 wk), PTBR (<37 wk)	Data split by country, no maternal obstetric outcomes
Gunby et al., 2005 (17), Canada	National registry	2001	22 clinics, 7,884 ART cycles; IVF- ICSI singletons: 1,141; IVF-ICSI twins: 958	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34 wk), BW, CA	Mean BW not documented (only in %), limited information on CA

Fertil Steril. Author manuscript; available in PMC 2021 November 09.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 1

Author	
Manuscrip	
Ť	

Author, year (ref), geographical area	Study design	Study period	Study characteristics	Data collection and adjustments	Outcome variables of interest	Comments
Gunby et al., 2006 (18), Canada	National registry	2002	21 clinics, 9,188 ART cycles; IVF- ICSI singletons: 1,359; IVF-ICSI twins: 1,228	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34wk), BW, CA	Mean BW not documented (only in %), limited information on CA
Gunby et al., 2007 (19), Canada	National registry	2003	24 clinics, 10,656 ART cycles; IVF- ICSI singletons: 1,621; IVF-ICSI twins: 1,378	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34wk), BW, CA	Mean BW not documented (only in %), limited information on CA
Gunby et al., 2008 (20), Canada	National registry	2004	26 clinics, 11,068 ART cycles; IVF- ICSI singletons: 1,804; IVF-ICSI twins: 1,286	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34wk), BW, CA	Mean BW not documented (only in %), limited information on CA
Gunby et al., 2009 (21), Canada	National registry	2005	25 clinics, 11,414 ART cycles, IVF- ICSI singletons: 1,909; IVF-ICSI twins: 1,534	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34wk), BW, CA	Mean BW not documented (only in %), limited information on CA
Gunby et al., 2010 (22), Canada	National registry	2006	25 clinics, 12,052 ART cycles; IVF- ICSI singletons: 2,123; IVF-ICSI twins: 1,692	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34wk), BW, CA	Mean BW not documented (only in %), limited information on CA
Gunby et al., 2011 (23), Canada	National registry	2007	26 clinics, 13,482 ART cycles; IVF- ICSI singletons: 2,461; IVF-ICSI twins: 1,948	Unadjusted data for all autologous and donor cycles	PNMR, MGA, PTBR (<37 wk), VPTBR (<34wk), BW, CA	Mean BW not documented (only in %), limited information on CA
Zegers-Hochschild et al., 2019 (24), Latin America	Latin American IVF registry	2016	15 countries, 85,474 ART cycles; IVF-ICSI singletons: 11,959; IVF- ICSI twins: 5,727	Unadjusted data for all autologous and donor cycles	PNM, MGA, PTB, VPTB, BW	Data from 178 clinics
Zegers-Hochschild et al., 2018 (25), Latin America	Latin American IVF registry	2015	15 countries, 75,121 ART cycles; IVF-ICSI singletons: 11,627; IVF- ICSI twins: 6,326	Unadjusted data for all autologous and donor cycles	PNM, MGA, PTB, VPTB, BW	Data from 175 clinics
Zegers-Hochschild et al., 2017 (26), Latin America	Latin American IVF registry	2014	15 countries; IVF-ICSI singletons: 11,373; IVF-ICSI twins: 6,398	Unadjusted data for all autologous and donor cycles	PNM, PTB, VPTB	Data from 159 clinics
Zegers-Hochschild et al., 2015 (27), Latin America	Latin American IVF registry	2013	15 countries, 85,474 ART cycles; IVF-ICSI singletons: 8,385; IVF- ICSI twins: 5,649	Unadjusted data for all autologous and donor cycles	PNM, MGA, PTB, RR for PM and VPTB	Data from 158 clinics
Sunderam et al., 2018 (28), U.S.	ART surveillance data, U.S.	2015	52 reporting areas, total of 182,111 ART procedures; ART twins: 22,491	Unadjusted data for all autologous and donor cycles	LBW, PTB, PTBR	Data from 464 clinics
Sunderam et al., 2017 (29), U.S.	ART surveillance data, U.S.	2014	52 reporting areas, total of 169,568 ART procedures; ART twins: 24,514	Unadjusted data for all autologous and donor cycles	LBW, PTB, PTBR	Data from 458 clinics
Sunderam et al., 2015 (30), U.S.	ART surveillance data, U.S.	2013	52 reporting areas, total of 160,521 ART procedures; ART twins: 24,607	Unadjusted data for all autologous and donor cycles	LBW, PTB, PTBR, HCC	Data from 467 clinics
Chambers et al., 2007 (31), Australia	Retrospective population cohort study	1993– 2003	Cohort of 5,005 mothers; cohort of 5,886 infants conceived after ART	ART treatment compared with general population	CD, MBAC, CHCC, BW, MBAC	Birth-admission costs calculated using Australian Refined Diagnosis Related Groups and weighted national average costs (2003–2004 Euros)

Author, year (ref), geographical area	Study design	Study period	Study characteristics	Data collection and adjustments	Outcome variables of interest	Comments
Felberbaum et al., 2007 (32), Germany	National registry study	2001	Data from Deutsches IVF-Register	Unadjusted data for all autologous and donor cycles	MGA, MBW, and PTBR	Data compared with ART rates in Europe
Makhseed et al., 1998 (33), Kuwait	Retrospective cohort study	1994– 1996	Single center; IVF-ICSI singletons: 58; IVF-ICSI twins: 31	Autologous, fresh IVF-ICSI cycles	GDM, PIH,PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Small cohort study
Callahan et al., 1994 (34), U.S.	Retrospective cohort study	1986– 1991	Single center university program; IVF-ICSI singletons: 11,986; IVF- ICSI twins: 1,135	Unadjusted data for all ART treatment	Charges for mother, infants, and total family	Included GIFT, review of medical and billing records, telephone survey for follow up
Goldfarb et al., 1996 (35), U.S.	Retrospective cohort study	1991– 1992	Single center university program; IVF-ICSI singletons: 36; IVF-ICSI twins: 28	Autologous, fresh IVF-ICSI cycles	MHA, NICU, HCC for infants	1991–1992 equivalent US\$
Rizk et al., 1991 (36), U.K.	Retrospective cohort study	1978 - 1987	Single center; IVF-ICSI singletons: 527; IVF-ICSI twins: 262	Unadjusted data for all IVF- ICSI treatments	PTBR, LBW, SBR	Data compared with national register
Merritt et al., 2014 (37), U.S.	Retrospective cohort study	2009– 2011	NA	Combined data for IVF- ICSI	SBR, PTB, ANH	In-patient admission data sets, may include small number of AI cycles
Luke et al., 2019 (38), U.S.	National data	2004– 2013	13 States: IVF-ICSI singletons: 97,852; IVF-ICSI twins: 40,406	Data for fresh IVF cycles using autologous oocytes	GDM, PIH,PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Data linkage through infant birth and death certificates, retrieved data only for ART group
Luke et al., 2019 (38), U.S.	National data	2004– 2013	13 States: IVF-ICSI singletons: 27,930; IVF-ICSI twins: 8,127	Data for frozen IVF cycles using autologous oocytes	GDM, PIH, PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Data linkage through infant birth and death certificates, retrieved data only for ART group
Luke et al., 2019 (38), U.S.	National data	2004– 2013	13 States: IVF-ICSI singletons: 13,875; IVF-ICSI twins: 8,586	Data for fresh IVF cycles using donor oocytes	GDM, PIH, PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Data linkage through infant birth and death certificates, retrieved data only for ART group
Luke et al., 2019 (38), U.S.	National data	2004– 2013	13 States: IVF-ICSI singletons: 5,965; IVF-ICSI twins: 1,801	Data for frozen IVF cycles using donor oocytes	GDM, PIH, PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Data linkage through infant birth and death certificates, retrieved data only for ART group
Dhont et al., 1999 (39), Belgium	Retrospective cohort study	1992– 1997	13 States; IVF-ICSI singletons: 3,057; IVF-ICSI twins: 1,241	Data for IVF and ICSI	MGA, MBW, PND, PNM, CA, CD	Data extracted from tables compared with controls
Pinborg et al., 2004 (40), Denmark	National cohort study	1997	IVF-ICSI singleton mothers: 764; non-IVF-ICSI win mothers: 739; IVF-ICSI singletons: 634; IVF-ICSI twins: 472	Data for all IVF-ICSI treatment cycles	MHA, PE, Sick leave, MBW, MGA	Data collected through questionnaire study of mothers of IVF-ICSI singletons and twins
Gerris et al., 2004 (41), Belgium	Prospective cohort study	2000– 2001	IVF-ICSI singletons: 33; IVF-ICSI twins: 12	Data for women who had DET	MHA, MGA, PTB, LBW, CD, MBW, NICU admission	Data for women who had DET

Fertil Steril. Author manuscript; available in PMC 2021 November 09.

Author Manuscript

Author Manuscript

Author Manuscript

Author, year (ref), geographical area	Study design	Study period	Study characteristics	Data collection and adjustments	Outcome variables of interest	Comments
FIVNAT register 1996 (42), France	National registry data	1986– 1993	IVF-ICSI singletons: 7,650; IVF- ICSI twins: 2,470	Data for all IVF-ICSI treatment cycles	MHA, MGA, PTB, LBW, CD, MBW, NICU admission	Data extracted from tables from ESHRE Capri workshop group manuscript
Stoop et al., 2012 (43), Belgium	Matched-pair analysis	1999– 2008	IVF-ICSI singletons: 148; IVF-ICSI twins: 57	IVF with oocyte donation	GDM, PIH, PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Individual data for singleton versus twins captured, variables defined
Stoop et al., 2012 (43), Belgium	Matched-pair analysis	1999– 2008	IVF-ICSI singletons: 148; IVF-ICSI twins: 157	IVF with autologous oocyte	GDM, PIH, PP, PA, CD, MGA, PTBR, EPTBR, VPTBR, MBW, NICU admission	Individual data for singleton versus twins captured, variables defined
Han et al., 2018 (44), People's Republic of China	Register-based cohort study	2004– 2014	٧٧	IVF and FET groups	СА	CA associated with individual system but no separate data for singletons and twins
Ombelet et al., 2005 (45), Belgium	Retrospective cohort study	1993 - 2003	IVF singletons: 3,974 IVF twins: 2,901	Data for IVF cycles	MGA, MBW, CD, PTBR, VPTBR, LBW, CA, NICU	CA combined for minor and major aspects
Ombelet et al., 2005 (45), Belgium	Retrospective cohort study	1993– 2003	ICSI singletons: 1,655; ICSI twins: 1,102	Data for ICSI cycles	MGA, MBW, CD, PTBR, VPTBR, LBW, CA, NICU	CA combined for minor and major aspects
Koivurova et al., 2002 (46), Finland (data)	Population-based cohort study	1990 - 1995	IVF-ICSI singletons: 152; IVF-ICSI twins: 103	Data for all IVF-ICSI treatment cycles	Prematurity, CA	Linkage to national hospital discharge register, Finnish data
Van Dorp et al., 2014 (47), the Netherlands	Nationwide perinatal registry	1992 - 2009	IVF singletons: 61; IVF twins: 49	IVF with oocyte donation	MGA, CD, FM, MBW, CA, PP, PA, PIH, GDM	Univariate analysis data
Van Dorp et al., 2014 (47), the Netherlands	Nationwide perinatal registry	1992 - 2009	IVF singletons: 192; IVF twins: 119	IVF fresh cycles	MGA, CD, FM, MBW, CA, PP, PA, PIH, GDM	Univariate analysis data
Ricciarelli et al., 2013 (48), Spain	Prospective cohort study	2008– 2009	IVF-ICSI singletons: 5830 IVF ICSI twins: 4175	Data for IVF-ICSI, FET, and PGD cycles	CA and prematurity	SB significantly lower in singletons
D'Souza et al., 1997 (49), U.K.	Retrospective cohort study	1984– 1991	IVF-ICSI singletons: 150; IVF ICSI twins: 100	Data for fresh IVF cycles using autologous oocytes	MGA, MBW, CD, CA	Minor and major CA combined
Farhi et al., 2013 (50), Israel	Retrospective cohort study	1997– 2004	IVF singletons: 1,680; IVF twins: 1,621	Data for frozen IVF cycles	MGA, CA	Minor and major CA combined
Farhi et al., 2013 (50), Israel	Retrospective cohort study	1997 - 2004	ICSI singletons: 2,646; ICSI twins: 3,095	Data for fresh ICSI cycles	MGA, CA	Minor and major CA combined
Goldsmith et al., 2017 (51), Australia	Retrospective cohort study	1994– 2002	IVF-ICSI singletons: 3,233; IVF- ICSI twins: 1,726	Data for IVF and ICSI	CD, MGA, MBW	Emergency and elective cesarean deliveries combined
Belva et al., 2008 (52), Belgium	Retrospective cohort study	NA	IVF singletons: 1,523; IVF twins: 1,251	Data for fresh IVF cycles	MBW, LBW, NICU admissions	Questionnaire data and physical examination of children
Belva et al., 2008 (52), Belgium	Retrospective cohort study	NA	IVF singletons: 281; IVF twins: 98	Data for frozen IVF cycles	MBW, LBW, NICU admissions	Questionnaire data and physical examination of children

Fertil Steril. Author manuscript; available in PMC 2021 November 09.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Outcome variables of Comments	W, LBW, NICU Questionnaire data and issions physical examination of children	W, LBW, NICU Questionnaire data and issions physical examination of children	W. LBW. PTBR, Total CA taken BR, EPTBR, NICU issions, CA	W, LBW, PTBR, Total CA taken BR, EPTBR, NICU issions	, LBW, PND, GDM, Massachusetts Outcomes , CD Study of Assisted Reproductive Technologies (MOSART)	MGA, MBW Birth registry of Norway		PTBR Crude CD rates, elective and emergency combined			đ	>	>			
MBW, LBW, NICU admissions MBW, LBW, NICU admissions MBW, LBW, PTBR, VPTBR, EPTBR, NICU admissions, CA	MBW, LBW, NICU admissions MBW, LBW, PTBR, VPTBR, EPTBR, NICU admissions, CA			MBW, LBW, PTBR, VPTBR, EPTBR, NICU admissions	PTB, LBW, PND, GDM, Massac PIH, CD Study o Reprod (MOS A		CD, MGA, MBW Birth re	CD, MGA, MBW CD, PTBR	CD, MGA, MBW CD, PTBR CD, MBW, PTB	CD, MGA, MBW CD, PTBR CD, MBW, PTB CD, MBW, PTB	CD, MGA, MBW CD, PTBR CD, MBW, PTB CD, MBW, PTB CD, MBW, PTB GDM, PE, PP, PA, PPHPTL, LBW	CD, MGA, MBW CD, PTBR CD, MBW, PTB CD, MBW, PTB CD, MBW, PTB GDM, PE, PP, PA, PPHPTL, LBW F PHHPTL, LBW	CD, MGA, MBW CD, PTBR CD, MBW, PTB CD, MBW, PTB CD, MBW, PTB GDM, PE, PP, PA, PPHPTL, LBW PPH, PTL, LBW MBW, LBW, PTBR, and school test scores	CD, MGA, MBW CD, PTBR CD, MBW, PTB CD, MBW, PTB CD, MBW, PTB GDM, PE, PP, PA, PPHPTL, LBW PROM, PPH, PTL, LBW MBW, LBW, PTBR, And school test scores SBR, BW, PTB, VPTBR	CD, MGA, MBW CD, PTBR CD, MBW, PTB CD, MBW, PTB CD, MBW, PTB GDM, PE, PR, PA, PHH, PE, GDM, PA, PP, PHH, PE, GDM, PA, PP, PROM, PPH, PTT, LBW MBW, LBW, PTBR, and school test scores SBR, BW, PTB, VPTBR SBR, BW, PTB, VPTBR	CD, MGA, MBW CD, MBW, PTBR CD, MBW, PTB CD, MBW, PTB CD, MBW, PTB GDM, PE, PR, PA, PP PPHPTL, LBW PIH, PE, GDM, PA, PP, PROM, PPH, PTL, LBW MBW, LBW, PTBR, and school test scores SBR, BW, PTB, VPTBR SBR, BW, PTB, VPTBR SBR, BW, PTB, VPTBR
							-	icles								
	Data for fresh ICSI cycles	Data for frozen ICSI cycles	Data for FET	Data for fresh transfers	Data for ART cycles		Data for ART cycles	Data for ART cycles Data for fresh IVF cycles using autologous oocytes						· · ·		· · ·
Study characteristics	ICSI singletons: 1,476; ICSI twins: 1,211	ICSI singletons: 381; ICSI twins: 155	IVF singletons: 827; IVF twins: 234	IVF singletons: 874; IVF twins: 464	IVF singletons: 6,480; IVF twins: 4,774		IVF singleton: 8,501; IVF twins: 5,341	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 32	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 32 ART singletons: 241; ART twins: 58	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 32 ART singletons: 241; ART twins: 58 ART singleton: 1,659; ART twins: 982	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 32 ART singletons: 241; ART twins: 58 ART singleton: 1,659; ART twins: 982 ART singletons: 1,453; ART twins: 803	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 58 ART singletons: 241; ART twins: 58 ART singletons: 1,659; ART twins: 982 ART singletons: 1,453; ART twins: 803 ART singletons: 2,836; ART twins: 1,930	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 32 ART singletons: 241; ART twins: 58 ART singletons: 1,659; ART twins: 982 ART singletons: 1,453; ART twins: 803 ART singletons: 2,836; ART twins: 1,930 IVF singletons: 961; IVF twins: 558	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 32 ART singletons: 241; ART twins: 58 ART singletons: 1,659; ART twins: 982 ART singletons: 1,453; ART twins: 983 ART singletons: 1,453; ART twins: 1,930 IVF singletons: 961; IVF twins: 558 IVF singletons: 961; IVF twins: 150	IVF singleton: 8,501; IVF twins: 5,341 IVF singletons: 14,014; IVF twins: 2,847 ART singletons: 116; ART twins: 58 ART singletons: 241; ART twins: 58 ART singleton: 1,659; ART twins: 982 ART singletons: 1,453; ART twins: 803 ART singletons: 1,453; ART twins: 1,930 IVF singletons: 2,836; ART twins: 558 IVF singletons: 961; IVF twins: 558 IVF singletons: 454; IVF twins: 150 IVF singletons: 454; IVF twins: 150 ICSI singletons: 703; ICSI twins: 386 ICSI singletons: 703; ICSI twins:
Study period	NA	NA	2008– 2013	2008– 2013	2004– 2008		1967– 2006	1967– 2006 2003– 2005	1967– 2006 2003– 2005 2013– 2013	1967– 2006 2003– 2005 2013– 2013 2013– 2013–	1967– 2006 2003– 2005 2010– 2010– 2013 2013 2014	1967– 2006 2003– 2005 2013 2010– 2013 2013– 2014 2013– 2013– 2013–	1967– 2006 2003– 2005– 2013– 2013– 2013– 2013– 2013– 2013– 2013– 1995– 1995–	1967- 2006 2003- 2013- 2013- 2013- 2014 2014 2014 2013- 2015 1998- 1998- 1998- 2002	1967- 2006 2003- 2005 2010- 2013 2016- 2014 2014 2015 1998- 1998- 1986- 1986- 2002	1967- 2005 2003- 2005- 2013- 2013- 2014 2013- 2014 1995- 1995- 1996- 1986- 2002 2002 2002 2002 2002 2002
Study design	stive				ohort		ised	ased ased	ased ased	ased	lsed	rseq	sed try-	sed sed	sed sed	
Š	Retrospective cohort study	Retrospective cohort study	Retrospective cohort study	Retrospective cohort study	Longitudinal cohort study		Population-ba cohort study	Population-b cohort study Retrospective population-b study	Population-b cohort study Retrospectiv population-b study Retrospectiv cohort study	Population-bi- cohort study Retrospective population-bi- study Retrospective cohort study Retrospective cohort study	Population-bi cohort study Retrospective population-bi study Retrospective cohort study Retrospective cohort study Retrospective cohort study	Population-bs cohort study Retrospective population-bs study Retrospective cohort study Retrospective cohort study Retrospective cohort study Retrospective cohort study	Population-baa cohort study Retrospective population-baa study Retrospective cohort study Retrospective cohort study Retrospective cohort study National regis based cohort	Population-ba cohort study Retrospective population-ba study Retrospective cohort study Retrospective cohort study Retrospective cohort study National regis based cohort Retrospective cohort study Retrospective cohort study Retrospective Retrospecti	Population-ba cohort study Retrospective population-ba study Retrospective cohort study Retrospective cohort study Retrospective cohort study National regis based cohort Retrospective cohort study Retrospective cohort study Retrospective cohort study Retrospective cohort study National regis based cohort Retrospective cohort study National regis based cohort Retrospective cohort study National regis based cohort Retrospective cohort study National regis based cohort Retrospective cohort study	Population-based cohort study Retrospective population-based study Retrospective cohort study Retrospective cohort study Retrospective cohort study National registry- based cohort Retrospective cohort study National registry- based cohort study Retrospective cohort study Retrospective cohort study

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

-
$\mathbf{\Sigma}$
~
-
5
+
<u> </u>
$\overline{\mathbf{a}}$
\mathbf{O}
-
\sim
\leq
01
b
ar
an
anu
anu
Ĕ
7
SDI
Ĕ
SDI
nuscri
nuscri
SDI
nuscri

Author Manuscript

PA = placental abruption; PE = preeclampsia; PGD = preimplantation genetic diagnosis; PIH = pregnancy-induced hypertension; PM = prematurity; PND = perimatal death; PNMR = perimatal mortality rate; PP = placenta previa; PPH = postpartum hemorrhage; PROM = premature rupture of membranes; PPROM = preterm premature rupture of membranes; PTB = preterm birth; PTBR = preterm bi birth admission cost; MBW = mean birth weight; MGA = mean gestational age; MHA = mean hospital admissions; MHS = maternal hospital stay; NA = not available; NICU = neonatal intensive care unit; hemolysis, elevated liver enzymes, low platelet count syndrome; HT = hormone treatment; ICSI = intracytoplasmic sperm injection; IVF = in vitro fertilization; LBW = low birth weight; MBAC = mean Note: AI = artificial insemination; ANH = antenatal hospitalization; ART = assisted reproductive technology; BW = birth weight; CA = congenital anomaly; CD = cesarean delivery; CHCC = combined maternal and fetal health care costs; CI = confidence interval; DET = double-embryo transfer; EPTBR = early preterm birth rate; ESHRE = European Society of Human Reproduction and Embryology; ET = embryo transfer; FET = frozen embryo transfer; FM = fetal malpresentation; GDM = gestational diabetes mellitus; GIFT = gamete intrafallopian transfer; HCC = health care cost; HELLPS = = preterm labor; RR = relative risk; SBR = stillbirth rate; SCBU = special care baby unit; VPTB = very preterm birth; VPTBR = very preterm birth rate.

A	
uthor N	
Manuscript	

Author Manuscript

Author Manuscript

TABLE 2

List of studies with social and societal outcomes associated with multiple pregnancies after in vitro fertilization/intracytoplasmic sperm injection.

Author, year (ref), geographical area	Study design	Study period	Study characteristics	Data collection and adjustments	Outcome variables of interest	Comments
Chambers et al., 2007 (31), Australia	Retrospective cohort study	2003	5,005 mothers and 5,886 live births; IVF-ICSI singletons: 4,087; IVF- ICSI twins: 1,774	Maternal age adjusted data	Average (combined) in patient birth episode costs	Equivalent of 2003 Euros
Motohashi et al., 2004 (63), Japan	Retrospective cohort study	1997–2002	Women with IVF singletons: 58; with IVF twins: 21	Control group in the study	Maternal costs, infant costs, and combined costs	USD equivalent of 2003 Japanese yen (\$1 = 120¥)
Pinborg et al., 2004 (40), Denmark	National cohort study	1997	IVF-ICSI singletons: 634; IVF- ICSI twins: 472	Stratified for maternal age and parity	Sick leave	Rate comparison and average number of weeks
Koivurova et al., 2007 (46), Finland	Population-based cohort study	1990–1995	IVF-ICSI singletons: 152; IVF- ICSI twins: 103	7-Year follow-up study	Postneonatal medical conditions and admission costs	Equivalent of 2004 Euros
Chambers et al., 2014 (64), Australia	Retrospective cohort study	1993–2003	IVF singletons: 2,266; IVF twins: 1,067	Follow up until 2008	Comprehensive economic and health services assessment of the frequency, duration, and cost of hospital admissions during the first 5 years of life for singleton, twin, and HOM children	Australian dollars converted to US\$
Lemos et al., 2013 (65), US	Retrospective cohort study	2005-2010	NA	Adjusted data	Health care costs	Equivalent of 2013 US\$
Gerris et al., 2004 (41), Belgium	Prospective study	2000–2001	IVF-ICSI singletons: 33; IVF-ICSI twins: 12	Data for women who had DET	Health care costs for mother and infants	Equivalent of 2004 Euros
Oliveness et al., 2005 (66), France	Questionnaire-based cohort study	1998–2001	Families with 2- to 5-year-old singletons 344; Families with 2- to 5-year-old twins 344	Standardized measurement techniques used	Matemal psychological well- being and child psychological development	Children followed up until 2003

Fertil Steril. Author manuscript; available in PMC 2021 November 09.

Note: DET = double-embryo transfer; HOM = higher-order multiple; NA = not available.

TABLE 3

Summary table of maternal outcomes for effect and heterogeneity: twins compared with singleton pregnancies after in vitro fertilization/intracytoplasmic sperm injection treatment.

Outcome	Heterogeneity I ² % (P value)	OR (95% CI)
Antenatal hospitalization	52 (.05)	2.6 (1.9–3.5)
Cesarean delivery	93 (<.01)	3.7 (3.3–4.1)
Gestational diabetes mellitus	58 (<.01)	1.2 (1.1–1.3)
Placental abruption	0 (.82)	1.3 (1.2–1.5)
Placenta previa	66 (.02)	0.8 (0.7-0.9)
Pregnancy-induced hypertension	78 (<.01)	2.0 (1.9-2.3)
Postpartum hemorrhage	91 (<.01)	2.2 (1.2-4.1)
Preterm labor	91 (<.01)	6.3 (3.6–11.0)
Preeclampsia	40 (.12)	1.9 (1.4–2.6)

Note: CI = confidence interval; OR = odds ratio.

TABLE 4

Summary table of fetal and neonatal outcomes for effect and heterogeneity: twin compared with singleton pregnancies after in vitro fertilization/intracytoplasmic sperm injection treatment.

Outcome	Heterogeneity, I ² % (P value)	OR (95% CI)
Congenital anomaly	0 (.84)	1.1 (1.0–1.2)
Preterm birth rate (<37 wk)	97 (<.01)	8.3 (7.8–8.9)
Early preterm birth rate (<32 wk)	88 (<.01)	3.5 (3.1–3.9)
Very preterm birth rate (<28 wk)	82 (<.01)	5.5 (5.2–5.9)
Low birth weight (<2,500 g)	89 (<.01)	10.6 (9.9–11.4)
NICU/SCBU admission rate	91 (<.01)	6.5 (5.8–7.3)
Perinatal mortality rate	0 (.49)	2.4 (2.1–2.8)
Stillbirth rate	36 (.09)	2.2 (1.8–2.6)
Mean birth weight (g)	95 (<.01)	-856 (880-832) ^a
Mean gestational age (wk)	95 (<.01)	$-2.9(-3.0 \text{ to } -2.8)^{a}$

Note: CI = confidence interval; NICU = neonatal intensive care unit; OR = odds ratio; SCBU = special care baby unit.

^aMean difference (95% CI).